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1. Introduction 
After cardiovascular diseases, cancer is the second most frequent cause of death in 
Germany (Becker and Holzmeier 2014). Despite the considerable efforts, cancer 
remains largely lethal. The malignant tumors are not just one disease, but have several 
things in common: among these are uncontrolled cell growth, the ability of cells to 
migrate and their invasiveness into normal tissue which may ultimately result in the 
formation of metastases. These processes are triggered by a combination of genetic 
and epigenetic changes, denoting phenotypic alterations. A number of chemicals are 
known cancer risk factors. Classic genotoxic carcinogens (GC) are electrophilic 
chemicals capable of producing cancer by directly altering the genetic material of 
target cells. Mechanisms of non-genotoxic carcinogens (NGC) are caused by events 
other than changes in the underlying DNA sequence; perturbations in DNA 
methylation and histone modification are examples. 
The main tool in identifying carcinogens is the experimental long-term chemical 
carcinogenesis bioassay in rodents, mainly mice and rats. This is time consuming and 
needs a large number of animals (Benigni et al. 2013). As the liver represents the main 
target organ for metabolism and toxification, searching for an early biomarker of NGC 
action to help to generate a tool reducing the requirement for long-term biological 
testing is desirable. NGC could then be deselected before non-clinical trials. The 
establishment of early biomarkers for NGC to reliably and robustly predict cancer 
development is one of the aims of the EU project MARCAR. The MARCAR consortium 
consists of industrial and academic partners, who are working in close collaboration. 
Funded under the Innovative Medicines Initiative Joint Undertaking, MARCAR is a 5 
year project (MARCAR 2010). The present thesis arose during MARCAR research from 
2011 up to and including 2014. 
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1.1 The Dlk1-Dio3 Imprinted Gene Cluster 
Recently, MARCAR partners identified Dlk1-Dio3 imprinted gene cluster non-coding 
RNAs as novel biomarker candidates for liver tumor promotion in rodents (Lempiainen 
et al. 2013). The Dlk1-Dio3 cluster located on mouse distal chromosome 12 and human 
chromosome 14q32, respectively, is the largest imprinted gene cluster, meaning mono 
allelic gene expression in a parent-of-origin dependent manner (Schuster-Gossler et al. 
1998, Miyoshi et al. 2000). Imprinted genes differentiate their parent-of-origin by 
parent characteristic epigenetic marks like methylations in CpG islands (Hore et al. 
2007). The Dlk1-Dio3 cluster is under the control of an imprinted control region (ICR), 
located several kilobases upstream of the lncRNA promoter (Benetatos et al. 2011). It 
contains two differentially methylated regions (DMR) which are the germline derived 
intergenic DMR (IG-DMR) and the postfertilization derived MEG3-DMR. The Dlk1-Dio3 
cluster (figure 1) consists of three paternally expressed protein coding genes including 
Dlk1 (delta like 1), Rtl1 (retrotransposon like 1) and Dio3 (type 3 iodothyronine 
deiodinase) as well as several maternally expressed large and small non-coding RNAs. 
Beside Rian (RNA imprinted and accumulated in nucleus, snoRNAs) and Mirg (micro 
RNA containing gene), containing 53 miRNAs, Meg3/ Gtl2 (maternally expressed 3/ 
gene trap locus 2) represents a large non-coding RNA on the maternal allele (Miyoshi 
et al. 2000, Zhou et al. 2012). Within MARCAR, Meg3/ Gtl2 was identified as one 
candidate early biomarker of rodent hepatocarcinogenesis. 
 
Figure 1: Structure of the Dlk1-Dio3 imprinted gene cluster (modified from da Rocha et al. 2008). It consists of 
three known protein genes named Dlk1, Rtl1 and Dio3 on the paternal allele and several non-coding RNAs, snoRNAs 
and miRNAs on the maternal inherited allele, among Gtl2, Rian (snoRNAs) and Mirg. Arrows indicate the expression 
status. The IG-DMR is methylated on the paternal allele. 
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Multiple RNA isoforms transcribed from murine Gtl2 have been reported (Schuster-
Gossler et al. 1998). The physiological and pathological functions of Gtl2 are largely 
unknown. Gtl2 bears antiproliferative functions by suppressing mouse double minute 2 
(MDM2) expression and stimulation of tumor suppressor p53, a known target gene in 
human cancer cells (Zhou et al. 2007). Gtl2 is also able to directly regulate 
retinoblastoma protein (Rb) phosphorylation thereby suppressing cell proliferation by 
the inhibition of M phase to G1 transition, too. Also an indirect way exists, which 
controls Rb via p16INK4a activation (Zhang et al. 2010, Zhang et al. 2010). Studies in 
Gtl2 knockout embryos of mice uncovered a relation between Gtl2 and angiogenesis, 
as these embryos were shown to express increased amounts of vascular endothelial 
growth factor (Gordon et al. 2010). Some long non-coding RNAs have been shown to 
regulate transcription of neighboring genes lying on the same chromosome in a cis 
acting mechanism (Royo and Cavaille 2008). Gtl2 has been reported to act as a 
cofactor of the polycomb repressor complex 2 (PRC2) by directing the chromatin 
modifying complex to Dlk1, thereby regulating Dlk1 gene expression (Zhao et al. 2010). 
Physiologically, Gtl2 is expressed in many tissues. It is highly expressed in normal 
adrenal cortex, pituitary gland and ovary compared to other human tissues (Assie et al. 
2014). Loss of Gtl2 expression has been found in all cancer cell lines investigated so far, 
derived from bladder, colon, breast, lung and liver (Braconi et al. 2011, Benetatos et al. 
2011, Zhou et al. 2012). Through reexpression of Gtl2 in cancer cell lines, cell 
proliferation could be obstructed (Zhou et al. 2012). Expression of MEG3 (MEG3 is the 
human orthologue of mouse Gtl2) is also lost in 82 % of hepatocellular cancers 
(Braconi et al. 2011) as well as in pituitary tumors, lung cancer and neuroblastoma, just 
to mention a few (Zhao et al. 2005, Hu et al. 2009, Astuti et al. 2005). Thus, Gtl2 is 
believed to be a tumor suppressor (Zhou et al. 2012) having a central role in 
carcinogenesis. 
Two Gtl2 knockout mouse models have been reported in literature. Takahashi et al. 
2009 created a Gtl2KO (knockout) mouse harboring a 10 kb deletion in exons 1-5. Mice 
carrying a maternal deletion have a milder phenotype and are able to survive 4 weeks, 
whereas mice with a paternal deletion suffer perinatal lethality, indicating that Gtl2 
plays an important role in embryonic development. Due to their short lifetime, these 
animals are unsuitable for tumor promotion experiments. Only homozygous mutants 
Introduction Page 4 
survive. Another mouse model exists with locus specific defects in miRNA expression 
(Cavaillé, unpublished), but is not available for further investigations. Hence, one aim 
of the present doctoral thesis was to create a mouse system with altered Gtl2 
expression in their hepatocytes to study Gtl2 dependent effects in vivo. 
Recent work of the MARCAR partners supported the carcinogenic relevance of 
Dlk1-Dio3 cluster genes by their genetic dependence on CAR and β-catenin signaling, 
two pathways essential for phenobarbital (PB) dependent liver tumor promotion 
(figure 2) (Lempiainen et al. 2013). 
 
Figure 2: Schematic illustration of the phenobarbital (PB) induced perturbations in Cyp2b10 and Dlk1-Dio3 cluster 
genes (modified after Lempiainen et al. 2013). PB activates CAR thus inducing Cyp2b10, the classic CAR target 
gene, and Dlk1-Dio3 cluster genes. On the other hand, β-catenin inhibits Cyp2b10 expression but upregulates Dlk1-
Dio3 cluster genes. Aberrant β-catenin signaling has to do with tumor formation. 
 
1.2 Constitutive Androstane Receptor 
The orphan nuclear constitutive androstane receptor (CAR) plays a crucial role in the 
induction of drug metabolism and transporter as well as secretion of both xenobiotics 
and endobiotics. Thus, CAR upregulates a set of genes that encode cytochrome P450 
2B, CYP2C, CYP3A, NADPH-cytochrome P450 reductase, sulfotransferases, 
glucuronosyltransferases and glutathione S-transferases (Ueda et al. 2002). Since the 
discovery of phenobarbital’s Cyp inducing potential (Remmer and Merker 1963), this 
anticonvulsant serves as a prototype for structurally diverse chemicals that induce 
CYP2B. Due to the fact that many pharmaceuticals can activate CAR, it forms a central 
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defense mechanism against their toxicity (Yamamoto et al. 2003). The ligand PB does 
not bind directly to cytoplasmatic CAR, rather ligand exposure activates CAR signaling 
by dissociation of the co-chaperons cytoplasmic CAR retention protein (CCRP) and 
Hsp90 leading to nuclear CAR translocation. This translocation is presumably 
dependent on receptor dephosphorylation by protein phosphatase PP2A. In the 
nucleus, CAR forms a heterodimer with RXR and binds to phenobarbital responsive 
enhancer elements like PBREM and DR4, where it activates transcription of known 
target genes (figure 3) (Kodama and Negishi 2006). 
 
Figure 3: Schematic illustration of CAR signaling pathway (Kakizaki et al. 2011). After activation of the cytosolic 
receptor CAR upon ligand exposure, the co-chaperons CCRP and Hsp90 dissociate and CAR translocates to the 
nucleus. This translocation is presumably dependent on receptor dephosphorylation by protein phosphatase PP2A. 
In the nucleus, CAR forms a heterodimer with RXR and binds to the PBREM, where it activates transcription of 
known target genes. Abbreviations: CAR constitutive androstane receptor; Hsp90 heatshock protein 90; PP2A 
protein phosphatase 2A; p phosphorylation; RXR retinoid X receptor; PBREM Phenobarbital responsive enhancer 
module. 
PB is no human carcinogen although it was used in humans a long time to treat 
epilepsy (Lamminpaa et al. 2002). Human hepatocytes are resistant to the ability of PB 
in increasing cell proliferation (Parzefall et al. 1991). In contrast, rodents chronically 
exposed to PB develop hepatocellular carcinoma (Peraino et al. 1971) since PB is the 
prototype of a non-genotoxic carcinogen that causes tumors without inducing DNA 
mutation. For more information on the use of PB in murine hepatocarcinogenesis, 
please refer to 1.4.2. No PB mediated induction of Gtl2 was observed in CARKO mice, 
indicating that CAR is necessary for PB dependent activation of the Dlk1-Dio3 cluster 
gene expression (Lempiainen et al. 2013). 
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1.3 Canonical Wnt Signaling Pathway 
As already mentioned above, not only CAR, but also β-catenin is crucial for Dlk1-Dio3 
cluster expression. Basal Gtl2 expression levels are reduced and PB mediated induction 
is extinct in Ctnnb1KO (Ctnnb1 encodes β-catenin) mice revealing the requirement of 
β-catenin for both basal and PB induced Gtl2 expression (Lempiainen et al. 2013). 
β-Catenin plays two major roles in the cell regulating cell adhesion as an integral 
component of the classic cadherin complex (Vestweber and Kemler 1984) and gene 
transcription via the Wnt/ β-catenin signaling pathway (Reya and Clevers 2005). 
Int-1, the first Wnt gene, was identified long time ago as a proto-oncogene after 
infection of mice with mouse mammary tumor virus. The name Wnt is a composition 
of the Drosophila segment polarity gene wingless (Wg) and integration-1 (Int-1) (Nusse 
and Varmus 1982, Rijsewijk et al. 1987). The canonical Wnt/ β-catenin signaling 
pathway (figure 4) is physiologically activated by Wnt glycoproteins which bind to the 
seven transmembrane receptor Frizzled/ low density lipoprotein receptor-related 
protein 5 or 6 (LRP5/6) complex at the cell surface. Aberrantly, genetic or epigenetic 
alterations affecting key players of the pathway are able to activate β-catenin 
signaling. In the absence of Wnt molecules β-catenin is phosphorylated in a cytosolic 
protein complex, called destruction complex, containing the proteins APC 
(adenomatous polyposis coli), Axin, GSK3β (glycogen synthase kinase 3β) and CK1 
(casein kinase 1) and primed for proteasomal degradation by phosphorylation and 
ubiquitinylation. With a Wnt ligand binding to its receptors, the destruction complex 
gets destabilized while GSK3β is phosphorylated. Thus β-catenin is stabilized, 
accumulates in the cytoplasm and translocates to the nucleus where it interacts with 
DNA-bound T cell factor (TCF)/ lymphoid enhancer factor (LEF) transcription factors 
(Reya and Clevers 2005), thereby activating known target genes required for 
proliferation and differentiation such as c-myc, Cyclin D1, MMP7 (matrix 
metalloprotease 7) and glutamine synthetase (GS) (Morin 1999, Cadoret et al. 2001, 
Sansom et al. 2005). 
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Figure 4: Simpliﬁed schematic overview of the canonical Wnt/ β-catenin signaling pathway (Zeller et al. 2013). (a) 
In the absence of Wnt molecules, β-catenin is phosphorylated in a cytosolic protein complex containing the proteins 
APC, Axin, GSK3β and CK1, and primed for proteasomal degradation. (b) When the Wnt ligand binds to the FZD 
receptor, β-catenin gets phosphorylated and the cytosolic protein complex becomes destabilized. Thus, β-catenin 
gets stabilized and translocates to the nucleus where it interacts with transcription factors, thereby activating 
known target genes. LRP, low density lipoprotein receptor-related protein; P, phosphorylation; DVL, disheveled; 
APC, adenomatous polyposis coli; GSK3β, glycogen synthase kinase 3β; CK1, casein kinase 1, TCF, t-cell factor; 
CCND1, cyclin D1; MMP7, matrix metalloprotease 7. 
 
Abnormal regulation of the Wnt/ β-catenin signaling pathway can lead to various 
diseases including different types of cancer (Polakis 2000, Logan and Nusse 2004). 
Inappropriate β-catenin stabilization and therefore signaling is observed in 
hepatocellular carcinoma (HCC), hepatoblastoma (HB), colorectal carcinoma, tumors of 
the mammary gland and several other neoplasia (Reya and Clevers 2005, Schmidt et al. 
2011). Nearly 40 % of human HCC harbor mutations in the proto-oncogene CTNNB1 
(encoding β-Catenin). These activating mutations are predominantly located in the 
codons 33, 37, 41 or 45 of exon 3 affecting the Ser-Thr-phosphorylation sites of 
β-catenin and thereby preventing its degradation (de La Coste et al. 1998, Miyoshi et 
al. 1998, Wong et al. 2001). As a consequence, Wnt targets like GS are overexpressed 
in Ctnnb1 mutated hepatocellular tumors (Loeppen et al. 2002). 
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1.4 Chemical Carcinogenesis 
Carcinogenesis, the term for malignant tumor formation, describes the stepwise 
transformation of a normal to a malignant cell as a multistage process. In 1990, Fearon 
and Vogelstein designed a model to explain the sequential genetic alterations during 
the multistep development of colorectal carcinoma (Fearon and Vogelstein 1990). 
According to their model, tumors are the result of the mutational inactivation of tumor 
suppressor genes linked to the activation of oncogenes. According to their model, 
mutations in at least five genes are required that affect signaling in cell proliferation, 
survival and death. Proto-oncogenes are genes, which result in a permanent active 
profuse expressed product upon initiation. Known examples are Raf, Ras and Ctnnb1, 
which, when constitutively activated in tumor cells, result in increased cell 
proliferation (Giles et al. 2003, Croce 2008, Wang et al. 2009). In contrast, tumor 
suppressors like APC and p53 are negative regulators; they are inactivated in tumor 
cells and loose their physiological function (Weinberg 1991). 
 
Figure 5: Chemical carcinogenesis stages (Oliveira et al. 2007) showing the way of a normal cell to cancer. 
 
A tumor with a diameter of 1 mm consists of one million cells (Aktories et al. 2013) and 
descends from one initial, normal cell which passes through steps of initiation and 
promotion. It escapes from apoptosis and shows an enhanced cell proliferation while 
accumulating genetic and epigenetic alterations (Trosko 2001). DNA damage is 
established as the first step in chemical carcinogenesis. After this irreversible initiation, 
the so formed initiated cell is susceptible to tumor promoters. Promoters are non-
genotoxic compounds that increase cell proliferation leading to preneoplastic lesions 
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(Oliveira et al. 2007). Tumor promotion is an at least partly reversible process and the 
promoter must be present for a long period of time (Butterworth et al. 1992). 
Prolonged treatment with tumor promoters or treatment with cytotoxic agents may 
lead to tumor formation, when the agents are given alone, probably due to the 
presence of spontaneously mutated initiated cells (Laskin et al. 1988). The 
transformation into a malignant cell is the last step in carcinogenesis (Klaunig et al. 
2000). 
 
1.4.1 Hepatocellular Malignancies 
MARCAR partners focus on liver malignancies, as the liver represents the major target 
organ for NGC. Liver cancer incorporates various histologically different primary 
hepatic neoplasms which comprise hepatocellular carcinoma (HCC) and 
hepatoblastoma (HB) amongst others. Hepatocellular carcinoma is the major 
malignant tumor in the liver, most prominent risk factors are chronic hepatitis B and C 
infection, alcohol abuse and aflatoxin B1 exposure (Farazi and DePinho 2006). Distinct 
genetic events are associated with HCC formation such as inactivation of the tumor 
suppressor p53 and the activation of Wnt signaling through mutations in β-catenin 
(Polakis 2000, Farazi and DePinho 2006). 
In contrast to HCC, HB is a rare liver neoplasm occurring in small infants and children 
(Darbari et al. 2003). Each year 0.5 in 100,000 children come down with this cancer 
(AWMFonline 2010). Recent analysis demonstrated an 80 % prevalence of mutations in 
CTNNB1 (Schmidt et al. 2011). More rarely, HB shelter genetic alterations affecting 
other members of the Wnt pathway (Oda et al. 1996, Koch et al. 2004). 
In addition to the detection of cancer by blood tests, medical ultrasonics and classical 
diagnosis based on tissue samples, non-invasive imaging technologies like high-field 
magnetic resonance imaging (MRI) and high resolution positron emission tomography 
(PET) have opened a new tool for the early detection of liver tumors. PET uses 
radiolabeled biomolecules which trace non-invasively specific pathways and 
pathologies while MRI creates morphological pictures with a spatial resolution in the 
µm range by means of magnetic fields and radio waves. By applying simultaneous both 
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non-invasive methods, sensitivity and specificity for early tumor detection can be 
increased. Early detection of preneoplastic lesions by non-invasive in vivo imaging 
technologies will probably help with screenings for unwanted carcinogenic effects. In 
this thesis, we wanted to visualize the growth of Ctnnb1 mutated liver tumors in a 
reporter mouse by non-invasive technologies. 
 
1.4.2 Induced Hepatocarcinogenesis in Mice 
In order to investigate genes involved in carcinogenesis, tumors have to be generated. 
Therefore, mice that are susceptible to chemically induced carcinogenesis are a useful 
model to study critical alterations occurring during hepatocarcinogenesis. Previous 
work demonstrated that liver tumors induced in C3H mice predominantly harbor 
mutations in either Ha-ras, B-raf or Ctnnb1. The resulting type of mutation depends on 
the treatment regimen. 
Mutations in the proto-oncogenes Ha-ras (Harvey rat sarcoma) and B-raf are attained 
by a single intraperitoneal application of the liver carcinogen diethylnitrosamine (DEN) 
to two week old mice (Jaworski et al. 2005). Ras proteins are small monomeric 
membrane bound GTPases that regulate cell division and apoptosis, processes often 
deregulated in tumors (Malumbres and Barbacid 2003). In contrast, about 80% of the 
generated liver tumors after one single DEN injection of mice at the age of 6 weeks 
followed by chronic administration of the prominent tumor promoter phenobarbital 
reveal Ctnnb1 mutations (Aydinlik et al. 2001). Ctnnb1 mutated liver tumors harbor 
high expression of glutamine synthetase (GS), the prototype marker for β-catenin 
activation (Loeppen et al. 2002, Cadoret et al. 2002). For experimental analysis the 
mouse strain C3H is suitable since it has been demonstrated that it is susceptible to PB 
promotion (Aydinlik et al. 2001) and shows a high incidence of spontaneous liver 
tumor formation (Buchmann et al. 1991), while C57BL/6 mice are more resistant. This 
susceptibility is linked to a marker called D1Mit33 on mouse chromosome 1 (Bilger et 
al. 2004). 
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1.5 Zonated Gene Expression in the Liver 
The gene expression patterns in Ha-ras and Ctnnb1 mutated tumors resembled those 
seen in periportally and pericentrally located hepatocytes in normal liver tissue. There, 
the same signaling pathways operate (Hailfinger et al. 2006). Periportal cells can be 
distinguished from pericentral cells based on their different gene expression profile 
(figure 6). Hepatocytes in pericentral areas exhibit high activity in metabolism of 
xenobiotics, bile acid synthesis and glycolysis as well as biotransformation. The signal 
triggering this gene expression profile is likely a Wnt-signal, presumably delivered by 
endothelial cells of the central veins, activating the Wnt dependent signaling cascade 
in the neighboring hepatocytes. Thus, marker enzymes like glutamine synthetase and 
several Cyps that are overexpressed in Ctnnb1 mutated tumors also serve as markers 
for perivenous gene expression (Hailfinger et al. 2006). Periportal areas are marked by 
high levels of gluconeogenesis, cholesterol biosynthesis, fatty acid and amino acid 
degradation (Gebhardt 1992, Jungermann 1995, Braeuning et al. 2006, Ghafoory et al. 
2013), displaying high expression of glucose-6-phosphatase (G6Pase) and E-cadherin, 
markers which are also characteristic for Ha-ras mutated tumors (Hailfinger et al. 
2006, Braeuning et al. 2007). 
 
Figure 6: Schematic illustration of zonated gene expression in the liver. The figure shows the blood flow, oxygen 
and hormone and β-catenin signaling gradient that influences liver zonation (Braeuning et al. 2006). 
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1.6 Aims and Objectives 
Aberrant expression of long non-coding RNA Gtl2/ MEG3, located on the Dlk1-Dio3 
imprinting cluster, is often observed in tumors. Recently, project partners identified 
Gtl2 as novel biomarker candidate for liver tumor promotion in rodents. The aim of 
this project was to elucidate the role of Gtl2 in hepatocarcinogenesis and to verify its 
role as a biomarker for NGC and a tumor suppressor. For this purpose, examinations 
on murine liver treated with different NGC and GC compounds were performed and 
completed by cell culture experiments generating a switchable Gtl2 expressing system 
for global gene expression analysis to identify potential target genes. Due to the lack of 
an appropriate knockout mouse model, Gtl2 was constitutively overexpressed in 
murine liver by the use of adenoviral Gtl2. 
Another goal was to life image the development of special liver tumors in an 
engineered glutamine synthetase reporter mouse by PET and MRI. This reporter 
mouse could also be used to generate a glutamine synthetase gene expression “atlas”, 
which indirectly predicts in which organs/ cells Wnt signaling is active in the adult and 
during development. 
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2. Material 
2.1 Laboratory Equipment 
Item Manufacturer product 
Autoclave Webeco, Selmsdorf, Germany Autoclave C 
Balance Mettler-Toledo, Gießen, 
Germany 
P1200 
Sartorius, Göttingen, Germany Analytic 
Sartorius, Göttingen, Germany CP922 
Mettler, Gießen, Germany Laborwaage K7 
Mettler, Gießen, Germany Laborwaage P1200 
Burner WLD-TEC, Göttingen, Germany Gasprofi 1 micro 
Camera Nikon, Düsseldorf, Germany Coolpix 950 
Raytest, Straubenhardt, 
Germany 
CSC Chemoluminescense 
detection module 
Zeiss, Oberkochen, Germany AxioCam MRc 
Centrifuge  Eppendorf, Hamburg, 
Germany 
5410 
Eppendorf, Hamburg, 
Germany 
5415D 
Eppendorf, Hamburg, 
Germany 
5417R 
Heraeus Instruments, Hanau, 
Germany 
Biofuge 13 
Heraeus Instruments, Hanau, 
Germany 
Megafuge 1.0R 
Hettich, Tuttlingen, Germany Mikro 200R 
Labnet, Edison, USA C1301P 
Cyrostat microtome Reichert-Jung, Wetzlar, 
Germany 
Frigucut 2800 
Drying oven Heraeus Instruments, Hanau, 
Germany 
 
Electrophoresis 
chambers 
GibcoBRL, Karlsruhe, Germany H6 
Bio-Rad, Munich, Germany Mini Protean II 
Heat sterilizer Heraeus Instruments, Hanau, 
Germany 
VTR 5022 
Homogenizer ART, Müllheim, Germany Miccra D-9 
Incubator Heraeus Instruments, Hanau, 
Germany 
BB 6220 CU 
Laminar flow BDK, Sonnenbühl, Germany Sterilbank UVF 6.12 F 
Magnetic separation 
module 
Promega, Mannheim, 
Germany 
 
Magnetic stirrer Janke & Kunkel, Staufen, 
Germany 
IKA Combimag RCT 
Janke & Kunkel, Staufen, IKA Mag RH 
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Germany 
Heidolph Instruments, 
Schwabach, Germany 
MR 80 
Microscope Leitz, Wetzlar, Germany Labovert FS 
Zeiss, Oberkochen, Germany Imager.M1 
Microwave Bosch, Stuttgart, Germany 600 W 
Multiwell plate reader Perkin Elmer, Waltham, USA 1420 Multilabel Counter 
Victor V3 
PCR machine PerkinElmer, Waltham, MA, 
USA 
GeneAmp PCR System 2400 
Bio-Rad, Munich, Germany MyCyclerTM thermal cycler 
pH meter WTW, Weilheim, Germany pH 522 
Photometer Peqlab, Erlangen, Germany NanoDrop ND-1000 
Power supply Pharmacia, Uppsala, Sweden LKB EPS 500/400 
Desaga, Wiesloch, Germany Desatronic 3x500/100 
GibcoBRL, Karlsruhe, Germany ST 305 
GibcoBRL, Karlsruhe, Germany ST 606 T 
Quantitative real-time 
PCR 
Roche Diagnostics, Mannheim, 
Germany 
LightCycler 1.5 
Shaker Braun, Melsungen, Germany Certomat HK 
Heidolph, Kelheim, Germany Titramax 1000 
Thermoblock Eppendorf, Hamburg, 
Germany 
5320 
Eppendorf, Hamburg, 
Germany 
5436 
UV illuminator Biometra, Göttingen, Germany TI 1 
Vortex mixer Bender & Hobein AG, Zurich, 
Switzerland 
Genie 2TM 
Water bath GFL, Burgwedel, Germany 1083 
Water purification 
system 
Merck Millipore, Billerica, MA, 
USA 
Milli Q Plus 
 
2.2 Expandable Items and Small Devices 
Item Manufacturer Type designation 
0.2 ml reaction tubes Peqlab, Erlangen, Germany - 
0.5 ml reaction tubes Eppendorf, Hamburg, 
Germany 
- 
1.5 ml reaction tubes Eppendorf, Hamburg, 
Germany 
- 
1.8 ml cyro tubes Nunc, Wiesbaden, Germany Cryo Tube Vials 
2 ml reaction tubes Eppendorf, Hamburg, 
Germany 
- 
6 ml polystyrene tubes BD, Heidelberg, Germany Falcon 2058 
15 ml tubes BD, Heidelberg, Germany Falcon 2096 
50 ml tubes BD, Heidelberg, Germany Falcon 2070 
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Cages Techniplast, Neumarkt, 
Germany 
Macrolon Typ 2 
Capillaries (for 
lightcycler) 
Roche Applied Science, 
Penzberg, Germany 
LightCycler Capillaries (20 
µl) 
Cell culture dishes  BD, Heidelberg, Germany Falcon 3003 
Cell culture plates BD, Heidelberg, Germany Falcon 3224 
BD, Heidelberg, Germany Falcon 3043 
BD, Heidelberg, Germany Falcon 3226 
Cell scraper Corning, USA Costar Cell Lifter 
Centrifuge adapter Roche Applied Science, 
Penzberg, Germany 
LightCycler Centrifuge 
Adapters 
Counting chamber Brand, Wertheim, Germany Fuchs-Rosenthal 
Cover slips Thermo Scientific, Schwerte, 
Germany 
30 mm diameter, #1 
Dako pen Dako, Glostrup, Denmark Pen S2002 
Disinfectant concentrate Braun, Melsungen, Germany Helipur 
Glassware Schott, Mainz, Germany - 
Glass pasteur pipette WU Mainz, Mainz, Germany - 
Glass pipette Brand, Wertheim, Germany 5 ml, 10 ml, 20 ml 
Gloves Ansell, Munich, Germany Micro Touch Hygrip 
Kimberly-Clark, Dallas, USA Safeskin Purple Nitrile 
Inoculating loop Greiner, Frickenhausen, 
Germany 
731165 
Microscope glasses R. Langenbrinck, 
Emmendingen, Germany 
26x76 mm 
Metal tweezers Eickemeyer, Tuttlingen, 
Germany 
- 
Schnitzer Steel, Portland, OR, 
USA 
- 
Metal scissors Hauptner, Dietikon, 
Switzerland 
- 
Needles (0.9 x 40 mm) BD, Heidelberg, Germany Microlance 3TM 
Parafilm Pechiney, Chicago, USA PM-996 
Q-tips Neolab, Heidelberg, Germany  
Scalpel Braun, Melsungen, Germany  
Sterile filter Millipore, Eschborn, Germany Steritop 0.22 µm 
Syringes BD, Heidelberg, Germany 1 ml BD slip-tip syringe 
Syringe filter Sartorius, Göttingen, Germany Minisart 
 
2.3 Chemicals and Biochemicals 
Reagent Manufacturer 
(3-Aminopropyl)triethoxysilane Sigma, Taufkirchen, Germany 
3-Amino-9-ethylcarbazole ICN Biochemicals, Aurora, USA 
Acetaminophen Sigma, Taufkirchen, Germany 
Acetic acid (100 %) Merck KgaA, Darmstadt, Germany 
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Acetone Sigma, Taufkirchen, Germany 
Accutase Sigma, Taufkirchen, Germany 
Acrylamide (30 %) Roth, Karlsruhe, Germany 
Agarose Peqlab, erlangen, Germany 
Ammonium persulfate Serva, Heidelberg, Germany 
Ampicillin sodium salt Sigma, Taufkirchen, Germany 
Ampuwa (sterile water) Fresenius Kabi Deutschland GmbH, Bad 
Homburg, Germany 
AMV Reverse Transcriptase 10 U/µl Promega, Mannheim, Germany 
Bacto agar Applichem, Darmstadt, Germany 
Bacto tryptone Applichem, Darmstadt, Germany 
Bacto yeast extract Applichem, Darmstadt, Germany 
Benzonase Sigma, Taufkirchen, Germany 
Biotin-16-UTP Roche Diagnostics, Mannheim, Germany 
Boric acid Merck KgaA, Darmstadt, Germany 
Bovine serum albumin Thermo Scientific, Schwerte, Germany 
Bradford protein assay  Biorad, Munich, Germany 
Bromodeoxyuridine Applichem, Darmstadt, Germany 
Bromophenol blue Serva, Heidelberg, Germany 
CaCl2 Sigma, Taufkirchen, Germany 
Calf intestinal alkaline phosphatase Life technologies, Darmstadt, Germany 
CDP-Star ready to use Life technologies, Darmstadt, Germany 
Chloral hydrate Riedel-de Haen, Seelze, Germany 
Chloroform Merck KgaA, Darmstadt, Germany 
Citric acid Applichem, Darmstadt, Germany 
Coelenterazine PJK, Kleinblittersdorf, Germany 
Coenzyme A PJK, Kleinblittersdorf, Germany 
Collagenase Sigma, Taufkirchen, Germany 
Complete Mini protease inhibitor cocktail 
Roche Diagnostics, Mannheim, Germany 
D-glucose-6-phosphate Sigma, Taufkirchen, Germany 
Diethylpyrocarbonate Sigma, Taufkirchen, Germany 
Digitonin Sigma, Taufkirchen, Germany 
Dimethylformamide Merck KgaA, Darmstadt, Germany 
Dithiothreitol Sigma, Taufkirchen, Germany 
D-luciferin PJK, Kleinblittersdorf, German 
DMEM/F12 Gibco, Life technologies, Darmstadt, 
Germany 
DMSO  Applichem, Darmstadt, Germany 
DNase I (10 U/µl) Roche Diagnostics, Mannheim, Germany 
dNTPs 100 mM Life technologies, Darmstadt, Germany 
dNTPs 2 mM Thermo Scientific, Schwerte, Germany 
Doxycycline Sigma, Taufkirchen, Germany 
dT20 primer Genaxxon, Ulm, Germany 
Dynabeads M-280 Streptavidin Life technologies, Darmstadt, Germany 
EDTA Merck KgaA, Darmstadt, Germany 
EGTA Merck KgaA, Darmstadt, Germany 
Entellan Merck KgaA, Darmstadt, Germany 
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Eosin G Merck KgaA, Darmstadt, Germany 
Ethanol Merck KgaA, Darmstadt, Germany 
Ethidium bromide Serva, Heidelberg, Germany 
Ficoll type 400 Sigma, Taufkirchen, Germany 
Geneticin sulfate G418 Biochrom, Berlin, Germany 
GeneRuler 100 bp plus DNA Ladder Thermo Scientific, Schwerte, Germany 
GeneRuler 1 kb DNA Ladder Thermo Scientific, Schwerte, Germany 
Glucose Roth, Karlsruhe, Germany 
Glutaraldehyde Serva, Heidelberg, Germany 
Glycerol Applichem, Darmstadt, Germany 
Glycine Roth, Karlsruhe, Germany 
H2O2 (30 %) Sigma, Taufkirchen, Germany 
HCl Merck KgaA, Darmstadt, Germany 
Hematoxylin Roth, Karlsruhe, Germany 
Hepes (acid) Roth, Karlsruhe, Germany 
HiPerFect Qiagen, Hilden, Germany 
Hoechst 33258 Life technologies, Darmstadt, Germany 
Hygromycin B InvivoGen, San Diego, USA 
I-Block Life technologies, Darmstadt, Germany 
Isopopanol Merck KgaA, Darmstadt, Germany 
Kaiser’s glycerol gelatin Merck KgaA, Darmstadt, Germany 
KAI(SO4)2 · 12 H2O Merck KgaA, Darmstadt, Germany 
KCl Merck KgaA, Darmstadt, Germany 
KH2PO4 Merck KgaA, Darmstadt, Germany 
K2HPO4 · 3 H2O Merck KgaA, Darmstadt, Germany 
Lead nitrate Merck KgaA, Darmstadt, Germany 
LiCl Roth, Karlsruhe, Germany 
Lipofectamine 2000 Life technologies, Darmstadt, Germany 
Maleic acid Merck KgaA, Darmstadt, Germany 
Methanol Merck KgaA, Darmstadt, Germany 
MgCl2 Roche Diagnostics, Mannheim, Germany 
MgCl2 · 6 H2O Merck KgaA, Darmstadt, Germany 
MgSO4 · 7 H2O Merck KgaA, Darmstadt, Germany 
Midori Green Advanced DNA stain Nippon Genetics, Düren, Germany 
Milk powder  Roth, Karlsruhe, Germany 
Mouse genomic DNA Promega, Mannheim, Germany 
NaC24H39O4 Sigma, Taufkirchen, Germany 
NaCl Merck KgaA, Darmstadt, Germany 
NaHCO3 Merck KgaA, Darmstadt, Germany 
Na2HPO4 · 2 H2O Merck KgaA, Darmstadt, Germany 
NaIO3 Merck KgaA, Darmstadt, Germany 
NaN3 Merck KgaA, Darmstadt, Germany 
NaOH Merck KgaA, Darmstadt, Germany 
NP-40 Sigma, Taufkirchen, Germany 
NTPs Life technologies, Darmstadt, Germany 
Opti-MEM I Gibco, Life technologies, Darmstadt, 
Germany 
Orange G Peqlab, Erlange, Germany 
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Passive Lysis Buffer 5x Promega, Mannheim, Germany 
pBR322 DNA-MspI digest NEB, Frankfurt, Germany 
Penicillin/streptomycin Biochrom, Berlin, Germany 
Pentobarbital Sigma, Taufkirchen, Germany 
Phenobarbital Sigma, Taufkirchen, Germany 
Proteinase K Boehringer, Mannheim, Germany 
Phenol Roth, Karlsruhe, Germany 
QuantiFast Probe PCR Master Mix Qiagen, Hilden, Germany 
QuantiTect Primer Assays Qiagen, Hilden, Germany 
QuantiTect SYBR Green Mix Qiagen, Hilden, Germany 
Random hexamer primers Genaxxon BioScience, Ulm, Germany 
Restriction endonuclease HindIII NEB, Frankfurt, Germany 
Restriction endonuclease PvuI NEB, Frankfurt, Germany 
Restriction endonuclease XbaI NEB, Frankfurt, Germany 
Restriction endonuclease XhoI NEB, Frankfurt, Germany 
Restriction 10x Buffer NEB, Frankfurt, Germany 
RiboRuler High Range RNA Ladder Thermo Scientific, Schwerte, Germany 
RNaseOUT recombinant ribonuclease 
inhibitor 
Life technologies, Darmstadt, Germany 
RNA Loading Dye Thermo Scientific, Schwerte, Germany 
SDS Serva, Heidelberg, Germany 
SOC medium Life technologies, Darmstadt, Germany 
Sodium acetate Merck KgaA, Darmstadt, Germany 
Sodium citrate Merck KgaA, Darmstadt, Germany 
Sucrose Merck KgaA, Darmstadt, Germany 
Swine serum (normal) Dako, Glostrup, Denmark 
T3 RNA Polymerase Life technologies, Darmstadt, Germany 
T7 RNA Polymerase Life technologies, Darmstadt, Germany 
Taq buffer 10x Thermo Scientific, Schwerte, Germany 
Taq polymerase (1 U/µl) Thermo Scientific, Schwerte, Germany 
Taq polymerase (5 U/µl) Thermo Scientific, Schwerte, Germany 
Tetramethylethylenediamine (TEMED) Serva, Heidelberg, Germany 
Transcription buffer 5x Life technologies, Darmstadt, Germany 
Tris-HCl Sigma, Taufkirchen, Germany 
Tris base Sigma, Taufkirchen, Germany 
TRIzol Life technologies, Darmstadt, Germany 
Trypsin-EDTA Biochrom, Berlin, Germany 
Tween 20 Sigma, Taufkirchen, Germany 
X-Gal substrate  Peqlab, Erlangen, Germany 
Xylene Merck KGaA, Darmstadt, Germany 
Xylene cyanol Sigma, Taufkirchen, Germany 
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2.4 Buffers and Solutions 
2.4.1 Eukaryotic Cell Culture 
DMEM/F12 
Reagent Amount 
DMEM/F12 6 g 
NaHCO3 1,22 g 
H2Odest ad 450 ml 
- adjust with HClconc to pH 7.2, filtrate sterile (pore size 0.22 μm), store at 4°C 
before use, add: 
- 10 % (v/v) FCS (heat inactivated at 56 °C for 30 min), 1 % (v/v) penicillin 
(10,000 U/ml)/ streptomycin (10 mg/ml) solution, store at 4 °C 
- for cultivation of stably transfected cells, add 0.5 % (v/v) geneticine (20 mg/ml) and 
0.1 % (v/v) hygromycin B (100 mg/ml) 
 
DMEM/F12 freezing medium 
Reagent Amount 
DMEM/F12 medium 90 ml 
DMSO 10 ml 
- store at 4°C 
 
100 mM hepes buffer 
Reagent Amount 
Hepes (acid) 11.92 g 
H2Odest ad 500 ml 
- adjust with NaOH to pH 7.4 
 
20 mg/ml geneticin solution 
Reagent Amount 
Geneticin sulfate G418 (activity 701 mg/g) 1.43 g 
100 mM hepes buffer pH 7.4 50 ml 
- filtrate sterile (pore size 0.45 µm), store at -20°C 
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100 mg/ml hygromycin B solution 
Reagent Amount 
Hygromycin B (activity 990 mg/g) 2.02 g 
100 mM hepes buffer pH 7.4 20 ml 
- filtrate sterile (pore size 0.45 µm), store at -20°C 
 
10x PBS 
Reagent Amount Final concentration 
NaCl 80 g 1,4 M 
KCl 2 g 27 mM 
KH2PO4 2 g 15 mM 
NaH2PO4 · 2 H2O 14,35 g 80 mM 
H2Odest ad 1000 ml  
- autoclave 40 min 
- working solution 1x PBS: dilute 1:10 with H2Odest 
 
2.4.2 Cell Treatment 
Doxycyline 
Reagent Amount Stock conc. Final conc. 
Doxycycline 10 mg 1 mg/ml 0.01-1 µg/ml 
H2Odest 10 ml   
- filtrate sterile (pore size 0.45 µm), protect from light, store in aliquots at -20°C 
 
NaCl 
Reagent Amount Stock conc. Final conc. 
NaCl 584 mg 1 M 15 mM 
H2Odest 10 ml   
- filtrate sterile (pore size 0.45 µm), store at 4°C 
 
LiCl 
Reagent Amount Stock conc. Final conc. 
LiCl 424 mg 1 M 15 mM 
H2Odest 10 ml   
- filtrate sterile (pore size 0.45 µm), store at 4°C 
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Phenobarbital solution 
Reagent Amount Stock conc. Final conc. 
Phenobarbital 25.4 mg 100 mM 30 mM 
H2Odest 1 ml   
- prepare fresh solutions before use 
 
5-Azadeoxycytidine solution 
Reagent Amount Stock conc. Final conc. 
5-Azadeoxycytidine 5 mg 10 mM 10 µM 
DMSO 2190 µl   
- store in aliquots at -20°C 
 
2.4.3 Perfusion 
Basal perfusion buffer 
Reagent Amount 
NaCl 12.6 g 
KCl 0.64 g 
MgSO4 · 7 H2O 0.54 g 
KH2PO4 0.3 g 
NaHCO3 3.62 g 
Hepes (acid) 7.16 g 
Glucose · H2O 3 g 
H2Odest ad 2000 ml 
- adjust to pH 7.2 and store at 4°C 
 
Perfusion buffer 
Reagent Amount 
EGTA 47,5 mg 
Basal perfusion buffer 500 ml 
- adjust to pH 7.2 and store at 4°C 
 
Collagenase buffer 
Reagent Amount 
CaCl2 290 mg 
Basal perfusion buffer 500 ml 
- adjust to pH 7.2, store at 4°C and add 250 mg collagenase before use 
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Washing buffer 
Reagent Amount 
CaCl2 290 mg 
Basal perfusion buffer 500 ml 
BSA 10 g 
- adjust to pH 7.2 and store at 4°C 
 
2.4.4 Prokaryotic Cell Culture 
LB medium 
Reagent Amount 
Bacto tryptone 10 g 
Bacto yeast extract 5 g 
NaCl 10 g 
H2Odest ad 1000 ml 
- adjust with NaOH to pH 7.0, autoclave for 40 min, store at RT 
- before use, add ampicillin to a final concentration of 0.1 mg/ml 
 
LB-agar plates 
Reagent Amount 
Bacto agar 15 g 
LB medium ad 1000 ml 
- autoclave 40 min, add ampicillin to a final concentration of 0.1 mg/ml at most 60°C 
- pour into 10 cm dishes, let cool down and store putting at the lid at 4°C 
 
LB-glycerol storing medium 
Reagent Amount 
LB medium 5 ml 
Glycerol 5 ml 
- filtrate sterile (pore size 0.45 µm) and store at -20°C 
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2.4.5 Reporter Gene Analysis 
DTT 
Reagent Amount Stock conc. Final conc. 
DTT 1.545 g 1 M 33.3 mM 
H2Odest 10 ml   
- filtrate sterile (pore size 0.45 µm) and store at -70°C 
 
Firefly luciferase buffer 
Reagent Amount 
ATP 292 mg 
Coenzym A 207 mg 
Tricine 3.58 g 
MgSO4 ⋅ 7 H2O 1.32 g 
Na2EDTA (200 mM, pH 8.0) 500 µl 
D-luciferin 132 mg 
H2Odest ad 1000 ml 
- adjust to pH 8.0 and cool on ice before adding D-luciferin, filtrate sterile (pore size 
0.22 µm), protect from light and store in aliquots at -70°C 
- before use, add 333 µl 1 M DTT per 10 ml firefly luciferase buffer 
 
1000x coelenterazine 
Reagent Amount 
Coelenterazine 0.605 mg 
Methanol 1 ml 
- protect from light and store in 50 µl aliquots at -70°C 
 
1 M KxPO4 pH 5.1 
Reagent Amount 
K2HPO4 ⋅ 3 H2O 22.82 g 
KH2PO4 34.02 
H2Odest 350 ml 
 
 
 
 
Material Page 24 
Renilla luciferase buffer 
Reagent Amount 
Na2EDTA (200 mM, pH 8.0) 11 ml 
KxPO4 buffer (1 M, pH 5.1) 220 ml 
NaCl 64.3 g 
NaN3 0.845 g 
BSA 0.44 g 
H2Odest ad 1000 ml 
- adjust to pH 5.0 with KOH, filtrate sterile (pore size 0.22 µm) and store in aliquots 
at -70°C 
- add 20 µl coelenterazine per 10 ml renilla luciferase buffer prior to use 
 
2.4.6 Gel Electrophoresis 
Agarose Gel Electrophoresis 
50x TAE buffer (pH 8.5) 
Reagent Amount 
Tris base 242 g 
EDTA (0.5 M, pH 8) 100 ml 
Glacial acetic acid 57.1 ml 
H2Odest ad 1000 ml 
 
6x loading buffers 
Reagent Amount 
Sucrose 50 g 
SDS 1 g 
Orange G dye 0.5 g 
H2Odest ad 100 ml 
 
GeneRuler 1 kb DNA ladder 
Reagent Amount 
1 kb DNA ladder 1 µl (1 µg/µl) 
6x loading buffer 1 µl 
H2Odest ad 7 µl 
 
GeneRuler 100 bp plus DNA ladder 
Reagent Amount 
100 bp plus DNA ladder 1 µl (1 µg/µl) 
6x loading buffer 1 µl 
H2Odest ad 7 µl 
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Acrylamide Gel Electrophoresis 
5x TBE buffer pH 8.3 
Reagent Amount 
Tris base 54 g 
EDTA (0.5 M, pH 8) 20 ml 
Boric acid 27.5 g 
H2Odest ad 1000 ml 
 
10x loading buffer 
Reagent Amount 
Bromophenol blue 25 mg 
Xylene cyanol 25 mg 
Ficoll type 405 1.5 g 
EDTA (0.5 M, pH 8) 1 ml 
H2Odest ad 10 ml 
 
10 % Ammonium persulfate 
Reagent Amount 
APS 1 g 
H2Odest ad 10 ml 
 
Ethidium bromide solution (0.5 µg/ml) 
Reagent Amount 
Ethidium bromide 0.5 mg 
H2Odest ad 1000 ml 
 
pBR322 DNA-MspI Digest 
Reagent Amount 
pBR322 DNA-MspI Digest (1 µg/µl) 10 µl 
10x loading buffer 10 µl 
H2Odest ad 50 µl 
 
2.4.7 Immunohistochemistry 
Carnoy’s fixative 
Reagent Amount 
Ethanol 60 ml 
Chloroform 30 ml 
Glacial acetic acid 10 ml 
- prepare shortly before use 
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Coating solution 
Reagent Amount 
(3-Aminopropyl)triethoxysilane 4 ml 
Acetone ad 200 ml 
 
10x 0.1 M citrate buffer pH 6 
Reagent Amount 
Citric acid (sodium salt) 29.41 g 
H2Odest ad 1000 ml 
 
Glucose-6-phosphatase staining solution 
Reagent Amount 
Tris-maleate (0.2 M) 100 ml 
H2Odest 133 ml 
2% lead nitrate 25 ml 
- add 250 mg D-glucose-6-phosphate (monosodium salt) shortly before use 
 
Lead nitrate (2 %) 
Reagent Amount 
Lead nitrate 2 g 
H2Odest ad 100 ml 
 
TB buffer pH 8.7 
Reagent Amount 
Tris base 6 g 
MgCl2 ⋅ 3 H2O 406 mg 
H2Odest ad 1000 ml 
 
TBS/ T pH 7.4 
Reagent Amount 
Tween 20 1 ml 
NaCl 8.76 g 
Tris base 2.42 g 
H2Odest ad 1000 ml 
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PBS/ S 
Reagent Amount 
NaCl 2.03 g 
BSA 1 g 
1x PBS ad 100 ml 
 
PBS/ T 
Reagent Amount 
Tween-20 0.2 ml 
1x PBS ad 100 ml 
 
Acetate buffer 
Reagent Amount 
Sodium acetate 6.48 g 
Glacial acetic acid 1.21 ml 
H2Odest ad 1000 ml 
 
3-Amino-9-ethylcarbazole (AEC) solution 
Reagent Amount 
3-Amino-9-ethylcarbazole 4 mg 
N,N-Dimethylformamide 1 ml 
Acetate buffer 14 ml 
H2O2 (30 %) 15 µl 
- dissolve first 2 components before adding acetate buffer 
- add H2O2 before use 
 
Alcoholic eosin solution 
Reagent Amount 
Eosin Y 0.8 g 
Ethanol (60 %) ad 200 ml 
- filter through fluted filter paper 
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Mayer’s Hematoxylin 
Reagent Amount 
Hematoxylin 1 g 
NaIO3 0.2 g 
KAI(SO4)2 ⋅ 12 H2O 50 g 
Chloral hydrate 50 g 
Citric acid 1 g 
H2Odest ad 1000 ml 
- dissolve first 3 components in H2Odest before adding chloral hydrate and citric acid 
 
0.2 M tris/ maleate buffer 
Reagent Amount 
Tris (base) 24.2 g 
Maleic acid 23.2 g 
H2Odest ad 1000 ml 
- adjust pH with 1 N NaOH to 6.5 
 
X-Gal staining solution 
Reagent Amount Stock conc. Final conc. 
X-Gal 100 mg 100 mg/ml 1 mg/ml 
DMF 1 ml   
- store at -20°C 
 
X-Gal staining buffer 
Reagent Amount 
K4[Fe
(II)(CN)6] 210 mg 
K3[Fe
(III)(CN)6] 160 mg 
MgCl2 ⋅ 6 H2O 40.6 mg 
NP-40 20 µl 
SDS 10 mg 
PBS ad 100 ml 
- add 1 % X-Gal staining solution before use 
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2.4.8 Western Blot 
10x Assay buffer 
Reagent Amount 
MgCl2 ⋅ 6 H2O 2.03 ml 
Tris (base) 24.2 g 
H2Odest ad 100 ml 
- adjust to pH 9.5 before adding MgCl2 ⋅ 6 H2O 
- for 1x Assay buffer dilute 1:10 with H2Odest 
 
2x Lämmli buffer 
Reagent Amount 
Glycerol 20 ml 
Tris (base) 1.51 g 
H2Odest 25 ml 
Bromphenol blue 4 mg 
β-Mercaptoethanol 10 ml 
SDS 4 g 
H2Odest ad 100 ml 
- adjust to pH 6.8 with HCl before adding bromphenol blue, β-mercaptoethanol and 
SDS 
- add H2Odest to a final volume of 100 ml and store in 1 ml aliqouts at -20°C 
 
10x SDS-PAGE running buffer 
Reagent Amount 
Glycine 144 g 
Tris (base) 30 g 
SDS (20 % solution) 50 ml 
H2Odest ad 1000 ml 
- for 1x SDS-PAGE running buffer dilute 1:10 with H2Odest 
 
10x Transfer buffer 
Reagent Amount 
Glycine 144 g 
Tris (base) 30 g 
H2Odest ad 1000 ml 
- for final working dilute 100 ml of 10x Transfer buffer with 200 ml methanol and 
700 ml H2Odest 
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2.4.9 RNA-Protein-Pulldown 
0.1 % DEPC-H2O 
Reagent Amount Final conc 
Dietylpyrocarbonate 1 ml 1 % (v/v) 
H2Odest ad 1000 ml  
- dissolve until stirring; incubate overnight at RT, autoclave 20 min 
 
Solution A 
Reagent Amount Final conc 
NaOH 1 g 0.1 M 
NaCl 0.73 g 0.05 M 
DEPC-H2O ad 250 ml  
 
Solution B 
Reagent Amount Final conc 
NaCl 0.73 g 0.1 M 
DEPC-H2O ad 250 ml  
 
1 M Tris pH 7.5 
Reagent Amount Final conc 
Tris base 121.1 g 1 M 
DEPC-H2O ad 1000 ml  
- adjust to pH 7.5 
- for 20 mM Tris dilute 1:50 with DEPC-H2O 
 
2x BW (binding and washing) buffer 
Reagent Amount Final conc 
Tris-HCl pH 7.5 1 ml 1 M Tris-HCl 10 mM 
EDTA 1 ml 0.1 M EDTA 1 mM 
NaCl 11.69 g 2 M 
DEPC-H2O ad 100 ml  
-for 1x BW buffer dilute 1:2 with DEPC-H2O 
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10x RNA-protein binding buffer 
Reagent Amount Final conc 
Tris-HCl pH 7.5 2 ml 1 M Tris-HCl 0.2 M 
NaCl 1.25 ml 4 M NaCl 0.5 M 
MgCl2 0.2 ml 1 M MgCl2 20 mM 
Tween 100 µl 1 % 
DEPC-H2O ad 10 ml  
 
2.4.10 Cell Fractionation 
Basic buffer 
Reagent Amount Final conc 
NaCl 8.776 g 150 mM 
Hepes 13.015 g 50 mM 
DEPC-H2O ad 1000 ml  
- adjust to pH 7.4 with HCl, filtrate sterile (pore size 0.45 µm), store at 4°C 
 
Digitonin buffer (cytosolic protein fractionation 
Reagent Amount Final conc 
Digitonin (50 mg/ml) 10 µl 50 µg/ml 
Basic buffer ad 10 ml  
-dissolve 50 mg digitonin in 1 ml of total buffer by heating the solution for 2 min on 
95°C, add dissolved digitonin to basic buffer and add 1 tablet Complete Mini protease 
inhibitor cocktail/ 7 ml basic buffer 
 
NP-40 buffer (organelle membrane-bound fractionation) 
Reagent Amount Final conc 
NP-40 1 ml 1 % (v/v) 
Basic buffer ad 100 ml  
- store at 4°C 
 
RIPA buffer (nuclear protein fractionation) 
Reagent Amount Final conc 
NaC24H39O4 250 mg 0.5 % (v/v) 
SDS (20 % solution) 250 µl 0.5 % (v/v) 
Basic buffer ad 50 ml  
- shortly before use, add appropriate volume of Benzonase (1 U/ ml) and store at 4°C 
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2.5 Primers 
2.5.1 Genotyping 
PCR-ID Forward primer (5’3’) Reverse primer (5’3’) Amplicon 
7656 CAGTTCAGACTCAAGGATCA
TGC 
CGAGCAAACCTACTGTGTAGAT
AGC 
304 bp (wt) 
403 bp (ki) 
 
2.5.2 Mutation analysis and sequencing 
Gene Forward primer (5’3’) Reverse primer (5’3’) Amplicon 
Ctnnb1 ACTCTGTTTTTACAGCTGACCT GAGCGCATGATGGCATGTCTG 248 bp 
 
2.5.3 Gtl2-T3 PCR 
Primer sequence (5’3’) length Tm [°C] GC [%] Amplicon 
Gtl2_F1 AGCACAGAAGACGAAGAGCTG 21 bp 59.8 52.4 
1924 bp 
Gtl2_R1 CAAGAAATTTATTGAAAGCACCAT 24 bp 54.2 29.2 
 
2.5.4 Gtl2 upstream region PCR 
Primer sequence (5’3’) length Tm [°C] GC [%] Amplicon 
Gtl2_T1
_F2 
CACCAGCGAGGACAAGCGACAA 23 bp 66 60.9 
1.3 kb 
Gtl2_T1
_R1 
CAAGAAATTTATTGAAAGCACCAT 24 bp 62.7 50 
Gtl2_T2
_3_F2 
CACCGAGTCACAGTGGCATCC 21 bp 63.7 61.9 
1.3 kb 
Gtl2_T2
_3_R 
GCTGGCTGGGTGGGGTTTA 19 bp 61 63.2 
Gtl2_fw
160 
GTTGCTGGACTTTCAGGTTATG 22 bp 58.4 45.5 
1.6 kb 
Gtl2_rev
1980 
CAGACCAGTGGCTTGCCTA 19 bp 58.8 57.9 
Gtl2_fw
1966 
CAAGCCACTGGTCTGGAAAT 20 bp 57.3 50 
1.8 kb 
Gtl2_rev
3611 
CCTAGGATGCCACTGTGACTC 21 bp 61.8 57.1 
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2.5.5 Sequencing 
Primer sequence (5’3’) 
CMV_for CAAATGGGCGGTAGGCGTGTA 
Gtl2Seq_388F ACAGCGAGGGACAAGCGACAA 
Gtl2Seq_1096F CGGAGGACACTTGGACTCTTGCC 
Gtl2Seq_1286R ACGAAGACGGCGACGGGAT 
pCMV4_Rneu CCAGCTTGGTTCCCGAATAGA 
Gtl2PromA_426R CAGAATTAGCCCTTGCTTTATC 
Gtl2PromA_845F GACCCTCCTTGTCTATGCTTG 
Gtl2PromA_994R CCATGCTGAGGGCTATTGT 
Gtl2PromA_1876R AGCCTTCTCCGCCTCCTC 
Gtl2PromM_306R GGAAGAAGCCAAACCTATGCTAA 
Gtl2PromM_987R GGGCCTCCACAGCAAAGT 
Gtl2PromM_1594R CGATGCACTTCGGAGGGTG 
M13-uni GTAAAACGACGGCCAGT 
M13-rev AACAGCTATGACCATG 
Gstm3_delR1 CCCGACTGCATCTGCGTGTT 
 
2.5.6 LightCycler PCR 
Gene Forward primer (5’3’) Reverse primer (5’3’) Amplicon 
18s rRNA Mm_Rn18s_3_SG QuantiTect Primer Assay 143 bp 
Dio3 Mm_Dio3_1_SG QuantiTect Primer Assay 143 bp 
Dlk1 Mm_Dlk1_1_SG QuantiTect Primer Assay 120 bp 
Meg3 Mm_Meg3_1_SG QuantiTect Primer Assay 148 bp 
Mirg Mm_Mirg_4_SG QuantiTect Primer Assay 168 bp 
Rian Mm_Rian_2_SG QuantiTect Primer Assay 149 bp 
Rtl1 Mm_Rtl1_2_SG QuantiTect Primer Assay 88 bp 
Meg3 Rn_RGD1566401_va.1_SG QuantiTect Primer 125 bp 
MEG3 Hs_MEG3_QF_1 QuantiFast Probe Assay 85 bp 
18s rRNA CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT 187 bp 
hCAR1 TGCAACTGAGTAAGGAGCAA
GAA 
AAGGGCTGGTGATGGATGAA 273 bp 
mCcnd1 GCGCCCTCCGTATCTTACTT TCCTCTTCGCACTTCTGCTC 113 bp 
mCdk2 CCCTGGATGAAGATGGACG ATCAGAGCCGAAGGTGGG 138 bp 
mCdk4 CACGCCTGTGGTGGTTAC GAGATTCGCTTATGTGGGTTA 342 bp 
mCyp2b10 TACTCCTATTCCATGTCTCCA
AA 
TCCAGAAGTCTCTTTTCACATG
T 
118 bp 
rCyp2b1 TATCTTGCTCCTCCTTGCTCTC ACACTCCTCTTTCCCATCCC 413 bp 
rCyp4a3 CAAGGCTGTCGAGGATCTAA
AC 
GATGCACATGGTGGTGTAAG
GT 
474 bp 
rGls2 GCACAAGTTCGTGGGCAAG
G 
GTGCATGAGGCTGAGGGTGTT 469 bp 
mGtl2-T1 TTTCTGTCTTGCCGAGTGG AGGAAGCAGTGGGTTGGAG 455 bp 
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mGtl2-T2 GGACTCTTGCCACATTAGCC
C 
ATTTTCTCCTCAGCCCTTTGTT 497 bp 
mGtl2-T3 GTCTTCCTGTGCCATTTGCT TTCATCAGTCAGTAGGTGGGT
CT 
416 bp 
mNr4a2 TCTCCCAAGCACGTCAAAGA ATTTCCCATCATACATTAGCAA
TC 
340 bp 
mOlfr612 CTCCCTATCCTCTTGAAGAGA
TTG 
TCACGGATCTGCTTGGTTTT 428 bp 
mPcna GATAAAGAAGAGGAGGCGG
TAA 
CTGGCATCTCAGGAGCAATC 277 bp 
rSds AAACAAGGCTGTAAACATTT
CGTC 
GTGATCTTGGGCAGGGTGA 491 bp 
mWdr20a AAGGCTGCCGACCTGAGTA AGAAACCCGTCCTGGCTCA 484 bp 
 
2.6 Antibodies 
Antigen Cyp1a2 
Manufacturer Gift of Dr. Roland Wolf, University of Dundee, 
Dundee, UK 
Catalog number - 
Source rabbit, polyclonal 
Application IHC, 1:1000 in PBS/ S 
 
Antigen Cyp2c 
Manufacturer Gift of Dr. Roland Wolf, University of Dundee, 
Dundee, UK 
Catalog number - 
Source rabbit, polyclonal 
Application IHC, 1:300 in PBS/ S 
 
Antigen GAPDH 
Manufacturer Millipore, Merck KGaA, Darmstadt, Germany 
Catalog number 2145925 
Source mouse, polyclonal 
Application WB, 1:1000 in I-Block PBS/ T 
 
Antigen Glutamine synthetase (GS) 
Manufacturer Sigma, Taufkirchen, Germany 
Catalog number G2781 
Source rabbit, polyclonal 
Application IHC, 1:1000 in PBS/ S 
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Antigen Histone H3 
Manufacturer Cell signaling, Danvers, USA 
Catalog number D1H2 
Source rabbit, polyclonal 
Application WB, 1:2000 in 5 % milk powder TBS/ T 
 
Antigen Mouse IgG 
Manufacturer Sigma, Taufkirchen, Germany 
Catalog number A2554 
Source goat, polyclonal 
Application IHC, 1:20 in blocking buffer, HRP conjugated 
 
Antigen Rabbit IgG 
Manufacturer Dako, Glostrup, Denmark 
Catalog number P0217 
Source swine, polyclonal 
Application IHC, 1:20 in blocking buffer, HRP conjugated 
 
Antigen Anti mouse 
Manufacturer Life technologies, Darmstadt, Germany 
Catalog number T2192 
Source goat, polyclonal 
Application WB, 1:10,000 in I-Block PBS/ T, AP conjugated 
 
Antigen Anti rabbit 
Manufacturer Life technologies, Darmstadt, Germany 
Catalog number T2191 
Source goat 
Application WB, 1:10,000 in 5 % milk powder TBS/ T, AP 
conjugated 
 
2.7 Vectors 
pCR3 mCAR1 
Information:  Vector expressing mCAR1 under the control of the constitutively  
   active promoter. 
Resistance:  Ampicillin 
Manufacturer: Negishi, NIEHS, Durham, USA 
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pTAluc/STF 
Information:  Vector expressing Firefly luciferase reporter under the control of  
   8x TCF/ LEF binding sites. 
Resistance:  Ampicillin 
Manufacturer: Source of the backbone: Clontech, Mountain View, USA 
 
pRL-CMV 
Information:  Vector expressing Renilla luciferase under the control of the  
   constitutively active cytomegaly virus promoter. 
Resistance:  Ampicillin 
Manufacturer: Promega, Mannheim, Germany 
 
pCMV4-Gtl2 
Information:  Vector expressing Gtl2-T3 under the control of a constitutively  
   active cytomegaly virus promoter, cloned by Viktoria Kramer- 
   Potapenja 
Resistance:  Ampicillin 
Manufacturer: Source of the backbone: Poellinger, Karolinska Institute,   
   Stockholm, Sweden 
 
pTRE-Tight-Gtl2 
Information:  Vector containing a modified Tet response element consisting of  
   the tet operator sequence (tetO) and a minimal CMV promoter  
   allowing rtTA-inducible expression of Gtl2-T3. 
Resistance:  Ampicillin 
Manufacturer: Source of the backbone: Clontech, Mountain View, USA 
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pTK-Hyg 
Information:  Vector containing a hygromycin-resistance gene for selection of  
   stably transfected cell clones. 
Resistance:  Ampicillin, hygromycin 
Manufacturer: Clontech, Mountain View, USA 
 
pSV2-neo 
Information:  Vector containing a neomycin-resistance gene for selection of  
   stably transfected cell clones. 
Resistance:  Neomycin, geneticin and ampicillin 
Manufacturer: Clontech, Mountain View, USA 
 
pTet-on advanced 
Information:  Component of the Tet-On Advanced expression system,   
   expressing the reverse tetracycline-controlled transactivator  
   protein (rtTA) under the control of the constitutively active CMV  
   promoter. 
Resistance:  Ampicillin 
Manufacturer: Clontech, Mountain View, USA 
 
pBlueScript SK(-)/ Gtl2-T3 
Information:  Vector containing Gtl2-T3, flanked by T7 and T3-RNA polymerase 
   binding sites, allowing in vitro transcription of Gtl2-T3. 
Resistance:  Ampicillin 
Manufacturer: Source of the backbone: Stratagene, La Jolla, USA 
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2.8 Cell lines 
Cell line Cell type Mutation status 
(Ctnnb1 exon 3) 
Reference 
70.4 mouse hepatoma, 
strain C3H/ He 
Ctnnb1 wt/wt Kress et al. 1992 
70.4 Tet on K23 stably transfected 
subclone of 70.4 
Ctnnb1 wt/wt Stiegler 2009 
70.4 UT K54 stably transfected 
subclone of 70.4 
Ctnnb1 wt/wt Köber 2013 
70.4 STF K15 stably transfected 
subclone of 70.4 
Ctnnb1 wt/wt Braeuning et al. 
2007 
53.2b mouse hepatoma, 
strain C57BL/ 6J 
Ctnnb1 wt/wt Kress et al. 1992 
Hepa 1c1c.7 mouse hepatoma, 
strain C57BL/ J 
Ctnnb1 del/--- Bernhard et al. 
1973 
55.1c mouse hepatoma, 
strain C57BL/ 6J 
Ctnnb1 wt/del Kress et al. 1992 
HC-AFW1 human HCC CTNNB1 del Armeanu-Ebinger et 
al. 2012 
 
2.9 Rodent strains 
Strain Sourcer 
C3H/ He N Charles River, Sulzfeld, Germany 
GS reporter mouse Taconic Artemis, Köln, Germany 
 
2.10 Kits 
Kit Manufacturer 
AdEasy Adenoviral Vector System Agilent Technologies, Böblingen, 
Germany 
Biotin Luminescent Detection Kit Roche Diagnostics, Mannheim, Germany 
Easyprep Pro Plasmid Mini Kit Biozym, Hessisch Oldendorf, Germany 
Expand Long Template PCR System Roche Diagnostics, Mannheim, Germany 
FastStart DNA MasterPLUS SYBR Green I Kit Roche Diagnostics, Mannheim, Germany 
Genopure Plasmid Maxi Kit Roche Diagnostics, Mannheim, Germany 
High Pure RNA Isolation Kit Roche Diagnostics, Mannheim, Germany 
peqGOLD Cycle Pure Kit Peqlab, Erlangen, Germany 
peqGOLD Gel Extraction Kit Peqlab, Erlangen, Germany 
QuantiFast Probe PCR Kit Qiagen, Hilden, Germany 
QuantiTect SYBR Green PCR Kit Qiagen, Hilden, Germany 
TOPO TA Cloning Kit Life technologies, Darmstadt, Germany 
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2.11 Tissue Samples 
Mouse liver samples from a tumor promotion experiment (Rignall et al. 2013) were 
available, in which the treatment with two PCBs (PCB 126 and PCB 153) lasted for 34 
weeks. 
Samples from chemically induced mouse liver tumors were available from an 
experiment previously conducted in our laboratory (unpublished). There, C3H mice 
have been treated with a single dose of DEN to induce Ras and Raf mutated tumors. 
After 6 months, animals received 0.05 % PB for 4 weeks. Tumors had been analyzed in 
terms of mutations of the Ha-ras and B-raf proto-oncogenes according to (Aydinlik et 
al. 2001, Jaworski et al. 2005). 
Liver samples from wild type mice as well as hCAR/ hPXR mice (Braeuning et al. 2014) 
treated with two different fungicides were available in our laboratory (unpublished). 
Also samples from rats, treated with two NGC (PB and CF) as well as two GC (AAF, 
NNM) were available (Ittrich et al. 2003). 
 
2.12 Software 
Software Manufacturer 
AxioVision 4.5 Zeiss, Oberkochen, Germany 
Adobe Photoshop Adobe Systems, San Jose, USA 
BioDraw Ultra 12.0 PerkinElmer, Waltham, USA 
Chromas Lite Technelysium, Bisbane, USA 
Corel Draw Graphics Suite 12 Corel Corporation, Ottawa, Canada 
CSC Camera Controler 1.11 Raytest, Traubenhardt, Germany 
EndNote X2 EndNote, Carlsbad, USA 
NanoDrop ND-1000 V3.2.1 PerkinElmer, Waltham, USA 
Office 2007 Microsoft, Redmond, USA 
OriginPro 8G Origin Lab Cooperation, Northampton, 
MA, USA 
Primer Premier 5.00 Premier Biosoft, Palo Alto, USA 
Roche LightCycler Run 5.32 Roche Diagnostics, Mannheim, Germany 
Victor Workout 1.5 Perkin Elmer, Waltham, USA 
Windows XP Microsoft, Redmond, USA 
Windows 7 Microsoft, Redmond, USA 
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3. Methods 
3.1 Animals 
3.1.1 Animal Housing 
Mice were singly kept in Makrolon type 2 cages at a 12 hour light/ dark cycle with 
water and food available ad libitum. The animals were treated with human care and all 
protocols were in compliance with institutional guidelines. 
 
3.1.2 Breeding of the GS Reporter Mouse 
Taconic Artemis generated a GS (glutamine synthetase) reporter mouse expressing 
three reporters (β-galactosidase, LacZ; thymidine kinase 1, Tk-1; and Firefly luciferase, 
FLuc) under the control of a GS promoter specifically activated in cells with active 
β-catenin signaling and therefore also in Ctnnb1 mutated cells. For higher tumor 
susceptibility, C57BL/ 6 GS mice were interbred with C3H/ He N every generation. 
Existence of the knock in the reporter allele (KI) was determined by PCR (3.1.3). 
 
 
 
Figure 7: Schema of the GS (glutamine synthetase, Glul) reporter mouse generation. The targeting strategy allows 
the generation of a constitutive Knock in (KI) of LacZ and a conditional and constitutive KI of Tk-1 and/ or FLuc in the 
Glul gene. The constitutive KI 1 / conditional KI allele is obtained after PhiC31-mediated removal of the puromycin 
resistance selection marker. This allele expresses a chimeric transcript encoding the Glul protein fused to T2A, LacZ, 
loxP, T2A, Tk-1, FRT, loxP, T2A, FLuc and FRT sequences. A cleavage at the T2A site results in the expression of Glul, 
LacZ-loxP, Tk-1-FRT-loxP and a FLuc-FRT protein under the control of the endogenous Glul promoter 
(TaconicArtemis 2012). 
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3.1.3 Genotyping 
Genotyping was performed from mouse genomic DNA via PCR. Animals were sedated 
with isoflurane to cut out a small piece of ear. DNA isolation was carried out by 
overnight proteinase K digestion followed by heat inactivation at 95°C for 15 min. 
   Table 1: Proteinase K digestion for genotyping 
Reagent Amount 
10x PCR buffer 8 µl 
Proteinase K (20mg/ml) 2 µl 
H2O sterile 70 µl 
Total volume 80 µl 
Cell fragments were pelletized by centrifugation at 13,000 rpm for 5 min. 5 µl of the 
DNA-containing supernatant was used for the genotyping PCR. 
Primers are listed in 2.5.1. 
   Table 2: PCR protocol for detecting the knock in reporter allele in the GS mouse 
Reagent Amount 
10x PCR buffer 5 µl 
MgCl2 (25 mM) 4 µ 
dNTPs (10 mM) 1 µl 
Primer 7656_F 1 µl 
Primer 7656_R 1 µl 
Taq polymerase (1 U/µl) 1 µl 
H2O sterile 35 µl 
DNA 5 µl 
Total volume 50 µl 
   Table 3: PCR conditions for detecting the knock in reporter allele in the GS mouse 
Step Temp. Time 
Activation 95°C 5 min 
Denaturation 95°C 30 sec 
Annealing 60°C 30 sec 
Elongation 72°C 1 min 
35 cycles 
 72°C 10min 
 
PCR product formation was determined by acrylamide gel electrophoresis. The wt 
allele showed a product at 304 bp, the constitutive knock in allele at 403 bp. 
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3.1.4 Organ Harvesting 
For organ harvesting, mice were anesthetized with a mixture containing 95 % CO2 and 
5 % O2 and killed by cervical dislocation around 10 a.m. to exclude circadian influences. 
The abdomen was opened, the liver bled by opening the vena cava, weighed and 
washed in cold PBS. Liver lobes were isolated and shock-frozen on dry ice before 
stored at -70°C or fixed in Carnoy’s solution or in 4 % paraformaldehyde for later 
paraffin embedment. 
 
3.1.5 Preliminary Reporter Testing in the GS Reporter Mouse 
Before further experiments, each of the three reporter genes was tested for its 
functionality. For FLuc reporter testing, activity of Firefly luciferase enzyme was 
measured in organ homogenates (3.8.1). For LacZ reporter testing, shock-frozen 
organs were processed and stained with X-Gal as described in 3.9.5. The Tk-1 
measurement was performed by Dr. Andreas Schmid at the laboratory of Preclinical 
Imaging and Imaging Technology in Tübingen according to 3.13. 
 
3.1.6 Section of the GS Reporter Mouse 
In cooperation with the Institute of Pathology and Neuropathology, Department 
Pathology, University of Tübingen, Prof. Dr. med. Bence Sipos and Dr. med. vet. Ursula 
Kohlhofer, 30 organs from male and female GS reporter mice were isolated, rolled in 
tissue-tek and shock-frozen on dry ice before cutting slices and staining with X-Gal 
(3.9.5). 
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3.1.7 Induction of Ctnnb1 mutated Liver Tumors in the GS Reporter Mouse 
Generation of liver tumors in male GS reporter mice was conducted as previously 
described (Moennikes et al. 2000). Mice were injected a single intraperitoneal dose of 
DEN (90 µg/g body weight) at the age of 8-9 weeks followed by a treatment-free 
period of 2 weeks. Animals were then treated with 0.05 % PB in the drinking water for 
25 weeks. Tumor formation was reported every 2-4 weeks starting at week 12 after 
DEN. 
 
3.1.8 Mutation Analysis 
Tumor areas were punched out with a cannula and digested with proteinase K for 1 h 
at 50°C followed by a heat inactivation step at 95°C for 20 min. 
   Table 4: Proteinase K digestion for mutation analysis 
Reagent Amount 
10x PCR buffer 5 µl 
Proteinase K (10 mg/ml) 2 µl 
H2O sterile 32 µl 
Total volume 39 µl 
 
DNA was amplified by PCR to screen for mutations in exon 3 of the Ctnnb1 gene using 
the following reaction mix (table 5) and PCR conditions (table 6). 
   Table 5: Reaction mix for the Ctnnb1 PCR 
Reagent Amount 
Genomic DNA 39 µl 
dNTPs (2 mM) 5 µl 
Primer_fwd (10 µM) 2.5 µl 
Primer_rev (10 µM) 2.5 µl 
BSA (20 mg/ml) 1 µl 
Taq polymerase (2 U/µl) 1 µl 
Total volume 51 µl 
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Table 6: Temperature program used for the Ctnnb1 PCR 
Gene Activation Denat and Elongation Annealing Cycles 
Ctnnb1 95°C 5 min 95°C, 58°C, 72°C à 1 min 72°C 10 min 40 
 
Aliquots of PCR products were checked on an acylamide gel for correct product 
amplification. Mutations in the Ctnnb1 gene were determined by sequencing the PCR 
product spanning exon 3 of the gene which encodes the critical phosphorylation sites. 
Sequencing was performed at 4baselab GmbH, Reutlingen, using primer pairs listed in 
table 2.5.2. 
 
3.1.9 Adenoviral Gene Transfer into C3H Mice 
The Gtl2 adenoviral construct was created in cooperation with Michael Mc Mahon, 
(Dundee, Scotland) using the AdEasy Adenoviral Vector System Kit (Agilent 
Technologies, Berkshire, United Kingdom). 
12 6 week old male C3H mice were injected with 6.2 ∙ 10	IFU in 200 µl PBS via tail 
vein. 6 animals received a GFP containing adenovirus as a control, 6 animals received 
the Gtl2 containing adenovirus. They were killed at two different time points (4 and 8 
days after injection) and the liver was harvested (3.1.4). 
 
Figure 8: Schema of the AdGtl2 study. 3 mice per group were injected with an adenovirus containing Gtl2 or GFP as 
a control. They were killed 4 or 8 days after injection. 
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3.2 Cell Culture 
3.2.1 General Remarks 
In order to prevent contaminations, all working steps had to be performed under 
sterile conditions. Therefore, culture media and solutions as well as consumables were 
either autoclaved (121°C, 1 bar, 40 min) or, if heat sensitive, sterile filtered. Glassware 
was sterilized for 4 h at 180°C. Additionally, work material was disinfected with 70 % 
ethanol before putting under the clean bench. Cultivation took place at 37°C and 5 % 
CO2 with almost saturated humidity. 
 
3.2.2 Medium Change and Cell Passaging 
When cells reached a confluence of about 90 %, they were passaged in order to 
prevent growth inhibition. Cells were washed with 1x PBS and detached from the dish 
using trypsin-EDTA. Enzyme activity was stopped by adding the culture medium before 
cells were singularized by pipetting up and down using an injection needle. A few 
drops of the cell suspension were dripped on a new dish filled with fresh culture 
medium. For experiments, cells had to be counted using a Fuchs-Rosenthal chamber to 
reach defined cell number before plating. 
 
3.2.3 Thawing and Freezing of Cells 
Frozen cells were thawed at room temperature. The suspension was transferred into 
prewarmed medium and centrifuged for 5 min at 900 rpm. Supernatant was sucked off 
and the cell pellet was resuspended in fresh culture medium. After 24 hours, the first 
medium change had to be conducted. 
For storage, conﬂuent cells were detached as described in 3.2.2 and centrifuged for 
5 min at 900 rpm. After aspirating the supernatant, the cell pellet was resuspended in 
3 ml freezing medium containing 10 % DMSO whereof 1 ml was filled into one 
prechilled cryo vial. The vials stayed 1 h on ice and overnight at -70°C. The following 
day they could be preserved in liquid nitrogen. 
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3.2.4 Transfection 
Plasmids expressing Gtl2 are introduced into cells via lipofection-based transient or 
stable transfection. Lipofectamine 2000 was used according to manufacturer’s manual. 
Cells were seeded in antibiotic-free medium 24 h prior to transfection. When they 
reached 60 % confluence, 0.8 µg plasmid and 1.6 µg Lipofectamine 2000 dissolved in 
Opti-MEM I were gently dropped onto the cells. Medium change stopped transfection 
4 h later. Cells were treated 24 h after transfection. 
Plasmids carrying reporter genes were introduced into the cells similarly. 
Stably transfected cell line 70.4 STF K15 (Braeuning et al. 2007), 70.4 Tet on K23 
(Stiegler 2009) and 70.4 UT K54 (Köber 2013) had been generated by cotrasfection of 
selection markers: 
  Table 7: Stably transfected cell line with included plasmids and resistance 
Cell Line Plasmid transfected Resistance 
70.4 STF K15 pTAluc/ STF 
pSV2-neo 
 
Geneticin 
70.4 Tet on K23 pTet-On Advanced 
pSV2-neo 
 
Geneticin 
70.4 UT K54 pTRE-Tight-Gtl2 
pTK-Hyg 
 
Hygromycin 
 
3.2.5 Tet-On Advanced Inducible System 
The Tet-On Advanced Inducible Gene Expression System (Clontech, Mountain View, 
USA) provides an opportunity for on-demand expression of a desired gene, in this case 
Gtl2. Gtl2 expression is thereby controlled by the tetracycline derivate doxycycline. 
The system consists of a Tet-on Advanced transactivator and a PTight inducible 
promoter. In the presence of doxycycline, Tet-On Advanced binds to the tetracycline 
response element PTight thus activating high level transcription from the inducible 
promoter. This promoter controls the transcription of downstream Gtl2 (figure 9). 
70.4 cells had been stably transfected with these vectors (see 3.2.4) and named 70.4 
UT K54. 
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Figure 9: Induction in the Tet-On Advanced System. The system consists of a Tet-on Advanced transactivator and a 
PTight inducible promoter. In the presence of doxycycline (Dox), Tet-On Advanced binds to the tetracycline response 
element PTight thus activating high level transcription from the inducible promoter. This promoter controls the 
transcription of downstream Gtl2. Modified after Clontech 2012. 
 
3.2.6 Transduction 
The Gtl2 adenoviral construct was created adapted from pTRE-Tight-Gtl2 in 
cooperation with Michael Mc Mahon (Dundee, Scotland) using the AdEasy Adenoviral 
Vector System Kit (Agilent Technologies, Berkshire, United Kingdom). 10 or 100 MOI 
(multiplicity of infection) were dropped on the cells followed by a medium change 
after 4 h. RNA isolation took place 24 h after transduction. 
 
3.2.7 Treatment 
Culture medium was sucked off and replaced by fresh medium with 1 % FCS containing 
the reagent in end concentration. Cells were treated for 24 or 48 h. Mode of action of 
the different compounds as well as their final concentration are listed in table 8. 
  Table 8: Treatment compounds with their mode of action and final concentration 
Reagent Mode of action Final con. 
5-Aza-dC Demethylation 10 µM 
Doxycycline Activation of the Tet 
system 
0.01-1 µg/ml 
LiCl Inhibition of GSK3β 15 mM 
Phenobarbital indirect CAR activator 30 mM 
Gtl2 
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3.3 Isolation and Cultivation of Primary Cells from Mouse Liver 
3.3.1 Preparation of Collagen-Coated Culture Dishes 
Sterile collagen fibers from rat tails were stirred overnight in sterile filtrated 0.05 % 
acetic acid at 4°C. Unsolved fibers were removed by centrifugation at 5000 g for 4 h 
and 4°C. Culture dish coating was carried out by pipetting the collagen solution onto 
the dish, let drying and incubating overnight with UV. 
 
3.3.2 Isolation of Primary Hepatocytes 
Mice were anesthetized with pentobarbital and disinfected at the abdominal area, 
before the abdominal wall was cut open. Liver had to be flushed through the vena 
porta to the open vena cava inferior. As soon as the blood had fully removed, the liver 
became soft, bright and showed structure while collagenase buffer rinsed in. The 
dissected hepatocytes were washed with washing buffer and pelletized by 
centrifugation at 50 g for 2 min before resuspended in washing buffer. Viability was 
checked and cells were seeded on collagen-coated dishes. After 5 h, they were 
attached to the dish. 
 
3.4 Quantitative Real-time PCR 
3.4.1 Isolation of RNA from Frozen Liver 
RNA was isolated from frozen liver tissue using TRIzol reagent according to the 
manufacturer’s protocol. The concentration of eluted RNA was measured on a 
NanoDrop ND-1000 photometer. After RNA isolation, DNase I digestion was performed 
in order to remove genomic DNA. 100 µg of RNA were treated with 25 U DNase I in a 
total volume of 100 µl for 1 h at 37°C and purified by phenol/ chloroform extraction 
and subsequent ethanol precipitation. 
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3.4.2 Isolation of RNA from Cell Culture 
RNA was isolated from cell culture using Roche High Pure RNA Isolation Kit according 
to the manufacturer’s protocol. The concentration of eluted RNA was measured on a 
NanoDrop ND-1000 photometer. After RNA isolation, DNase I digestion was performed 
in order to remove genomic DNA. Complete RNA was treated with 25 U DNase I in a 
total volume of 50 µl for 1 h at 37°C and purified by phenol/ chloroform extraction and 
subsequent ethanol precipitation. 
 
3.4.3 Reverse Transcription 
Reverse transcription of isolated RNA was carried out using the GeneAmp PCR System 
2400 (PerkinElmer, Waltham, USA) or MyCyclerTM thermal cycler (Bio-Rad, Munich, 
Germany) for 1 hour at 42 °C followed by a heat inactivation step of 15 min at 95°C. 
The following reaction mix was used: 
   Table 9: Reaction mix for reverse transcription of isolated RNA 
Reagent Amount 
10x PCR buffer 1.5 µl 
MgCl2 (25 mM) 3 µl 
dNTPs (10 mM) 1.5 µl 
dT20 (500 ng/µl) 0.38 µl 
dN6 (500 ng/µl) 0.38 µl 
AMV-RT (10 U/µl) 0.39 µl 
H2O sterile 4.85 µl 
RNA (125 ng/µl) 3 µl 
Total volume 15 µl 
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3.4.4 LightCycler PCR 
Quantitative real-time PCR was carried out on a LightCycler 1.5 instrument (Roche 
Applied Science, Penzberg, Germany) using either the FastStart DNA MasterPLUS SYBR 
Green I kit (Roche) or the QuantiTect SYBR Green PCR kit or QuantiFast Probe PCR kit 
(both Qiagen, Hilden, Germany). Primers were either synthesized by Eurofins MWG 
GmbH (Ebersberg, Germany) or obtained as predesigned primer assays from Qiagen 
and used with the QuantiTect or QuantiFast PCR kits according to the manufacturer’s 
instructions. The temperature programs for the designed primers are listed in table 10 
(for primer sequences see 2.5.6). 
Table 10: Temperature programs used for LightCycler PCR 
Gene Activation Denaturation Elongation Annealing Cycles 
18s rRNA 95°C 10 min 95°C 5 s 68°C 5 s 72°C 8 s 35 
hCAR1 95°C 10 min 95°C 7 s 62°C 6 s 72°C 6 s 45 
mCcnd1 95°C 10 min 95°C 6 s 65°C 6 s 72°C 4 s 50 
mCdk2 95°C 10 min 95°C 6 s 65°C 6 s 72°C 5 s 45 
mCdk4 95°C 10 min 95°C 7 s 65°C 6 s 72°C 12 s 50 
mCyp2b10 95°C 10 min 95°C 0 s 57°C 5 s 72°C 5 s 60 
rCyp2b 95°C 10 min 95°C 7 s 63°C 6 s 72°C 17 s 50 
rCyp4a 95°C 10 min 95°C 7 s 66°C 6 s 72°C 18 s 50 
rGls2 95°C 10 min 95°C 7 s 66°C 6 s 72°C 17 s 50 
mGtl2-T3 95°C 10 min 95°C 7 s 64°C 6 s 72°C 15 s 45 
mNr4a2 95°C 10 min 95°C 5 s 62°C 6 s 72°C 8 s 50 
mOlfr612 95°C 10 min 95°C 7 s 59°C 6 s 72°C 19 s 45 
mPcna 95°C 10 min 95°C 5 s 58°C 6 s 72°C 10 s 50 
rSds 95°C 10 min 95°C 7 s 66°C 6 s 72°C 17 s 50 
mWdr20a 95°C 10 min 95°C 7 s 66°C 6 s 72°C 17 s 45 
 
3.5 Global Gene Expression Analysis 
Global gene expression analysis was performed on Affymetrix Mouse Gene ST 2.1 
Array chips by Dr. Michael Bonin, Microarray Gene Chip Facility, Institute of Medical 
Genetics, Tübingen. Michael Römer, Department of Computer Science, Cognitive 
Systems, Tübingen, conducted the analysis, where he filtered out genes with less than 
50 % deregulation. 
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3.6 Electrophoresis 
3.6.1 Agarose Gel Electrophoresis 
Agarose was dissolved in 1x TAE by boiling in a microwave for 2 min. After cooling 
down, 0.003 % Midori Green Advanced DNA stain (Nippon Genetics, Düren, Germany) 
was added for later visualization and the gel was poured in the chamber. DNA samples 
were prepared with 6x DNA loading buffer while 2x RNA loading dye was used for RNA 
samples and applied in parallel with a size marker. Gel run was performed in 1x TAE 
with 90 V for 60 min. Afterwards, the gel was photographed under UV light using a CSC 
Chemoluminescense detection module (Raytest, Straubenhardt, Germany). 
 
3.6.2 Acrylamide Gel Electrophoresis 
Acrylamide gel mix was prepared according to table 11. After polymerization, the gel 
was poured into a rack. DNA samples were prepared with 6x DNA loading buffer and 
applied in parallel with a size marker. Gel run was performed in 1x TBE with 300 V for 
70 min. Afterwards, the gel was stained with ethidiumbromide (0.5 µg/ml) for 10 min 
and photographed under UV light using a CSC Chemoluminescense detection module 
(Raytest, Straubenhardt, Germany). 
Table 11: Mix for acrylamide gels 
Reagent Amount 
H2Odest 16.6 ml 
5x TBE 7.2 ml 
Acrylamide (30 %) 12 ml 
10 % APS 200 µl 
TEMED 30 µl 
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3.7 Plasmid Preparation 
3.7.1 Amplification of Gtl2-T3 
Gtl2-T3 was amplified of cDNA transcribed from Ctnnb1 mutated mouse liver tumor 
tissue using the Expand Long Template PCR System (Roche Diagnostics, Mannheim, 
Germany) and the following PCR conditions: 
   Table 12: PCR protocol for amplification of Gtl2-T3 
Reagent Amount 
10x buffer 1 5 µl 
dNTPs (10 mM) 1.75 µl 
Primer Gtl2_F1 (20 µM) 1 µl 
Primer Gtl2_R1 (20 µM) 1 µl 
Polymerase-mix 0.75 µl 
H2O sterile 37.5 µl 
cDNA 3 µl 
Total volume 50 µl 
 
   Table 13: PCR conditions or amplification of Gtl2-T3 
Step Temp. Time 
Activation 94°C 2 min 
Denaturation 94°C 10 sec 
Annealing 59°C 30 sec 
Elongation 68°C 2 min 
10 cycles 
Denaturation 94°C 15 sec 
Annealing 59°C 30 sec 
Elongation 68°C 2 min + 2 sec 
25 cycles 
 72°C 7 min 
 
PCR product formation was determined by agarose gel electrophoresis, showing 
Gtl2-T3 at 1.9 kb. 
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3.7.2 Amplification of Gtl2 upstream regions 
Gtl2 upstream regions were amplified of mouse genomic DNA (Promega, Mannheim, 
Germany) using the Expand Long Template PCR System (Roche Diagnostics, 
Mannheim, Germany), the following primer pairs and PCR conditions: 
  Table 14: PCR primer combinations for amplification of Gtl2 upstream regions 
Fragment Primer F Primer R 
Prom_T1 Gtl2_T1_F2 Gtl2_T1_R1 
Prom_T2_3_A Gtl2_fw160 Gtl2_rev1980 
Prom_T2_3_M Gtl2_fw1966 Gtl2_rev3611 
Prom_T2_3_E Gtl2_T2_3_F2 Gtl2_T2_3_R 
   Table 15: PCR protocol for amplification of Gtl2 upstream regions 
Reagent Amount 
10x buffer 1 5 µl 
dNTPs (10 mM) 1.75 µl 
Primer F (20 µM) 1 µl 
Primer R (20 µM) 1 µl 
Polymerase-mix 0.75 µl 
H2O sterile 39 µl 
gen. mouse DNA 1.5 µl 
Total volume 50 µl 
   Table 16: PCR conditions for amplification of Gtl2 upstream regions 
Step Temp. Time 
Activation 94°C 2 min 
Denaturation 94°C 10 sec 
Annealing 59°C 30 sec 
Elongation 68°C 2 min 
10 cycles 
Denaturation 94°C 15 sec 
Annealing 59°C 30 sec 
Elongation 68°C 2 min + 2 sec 
25 cycles 
 72°C 7 min 
 
PCR product formation was determined by agarose gel electrophoresis, both Prom_T1 
and Prom_T2_3 showing a product at 1.3 kb, while Prom_T2_3_A was 1.6 kb and 
Prom_T2_3_M was 1.8 kb. 
 
Methods Page 54 
3.7.3 Cloning Strategy 
All four fragments of the Gtl2 upstream region were cloned into pT81luc by means of 
the TOPO TA Cloning Kit (Life technologies, Darmstadt, Germany) according to 
manufacturer’s instruction. First, fragments were subcloned into pCR2.1-TOPO by the 
advantage of the terminal transferase activity of Taq polymerase adding a single A 
overhang to the PCR product, thus cloning it directly into the linearized vector. Ligation 
activity was raised by the presence of topoisomerase I. Positive clones could then be 
selected via blue-white-screening before desired fragments were cut out through 
overnight digestion using HindIII and XhoI. Subsequent dephosphorylation and 
purification of the backbone prepared Prom_T1, Prom_T2_3_A, Prom_T2_3_M and 
Prom_T2_3_E for their introduction into pT81luc target vector. Correct insertion was 
determined by sequencing. 
 
3.7.4 Plasmid Progeny and Isolation 
Bacteria can be easily used to propagate desired vectors using frozen stocks. A small 
amount of a stock was transferred into LB medium containing vector specific selective 
antibiotics. Bacteria culture grew overnight at 37°C. Depending on the quantity, 
plasmid isolation was performed with Easyprep Pro Plasmid Mini Kit (Biozym, Hessisch 
Oldendorf, Germany) or Genopure Plasmid Maxi Kit (Roche Diagnostics, Mannheim, 
Germany) according to manufacturer’s instruction. Both isolation procedures are 
based on a modified alkaline lysis protocol followed by binding of the plasmid DNA to 
the anion-exchange material in the column, washing with high salt buffers and 
subsequent elution in H2Odest. 
If no glycerol stock was available, vectors had to be transformed into One Shot TOP10 
chemically competent e.coli (Life technologies, Darmstadt, Germany) as described by 
the manufacturer. 
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3.7.5 DNA Quantification 
Determination of the DNA concentration and purity was carried out measuring the 
optical density at 260 nm with the NanoDrop ND-1000 (Peqlab, Erlangen, Germany). 
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 ratio indicates the purity of the DNA solution; it shall reside 
between 1.8 and 2. Such pure DNA could be used for further experiments. 
 
3.8 Luciferase Assays 
3.8.1 Firefly Luciferase Measurement in Homogenate of GS mice 
To measure FLuc reporter activity in GS mice, desired organs were isolated, weighed 
and washed in cold PBS. Every shock-frozen organ was homogenated in PBS. After lysis 
of cells with 1x PLB, the activities of Firefly luciferase enzyme was detected via 
measurement of generated luminescence at the multiwell plate reader 1420 Multilabel 
Counter Victor V3 (Perkin Elmer, Waltham, USA). The assay was calibrated with 
recombinant luciferase to allow an estimation of the amount of enzyme per tissue 
unit. 
 
3.8.2 Duale Luciferase Reporter System 
Reporter systems are important tools for the analysis of eukaryotic gene expression. 
Thereby, a reporter plasmid is used expressing the Firefly luciferase gene under the 
control of a promoter of interest. Enhanced activation of the gene of interest can 
easily be detected concerning to increased Firefly luciferase activity accompanied with 
luminescence. Due to varying transfection efficiencies, Renilla luciferase controlled by 
a constitutive active CMV promoter is used as a standard. 
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For preparation, cells were washed with 1x PBS. Lysis took place for 20 min under 
gentle shaking with 1x PLB. Generated luminescence was measured at the multiwell 
plate reader 1420 Multilabel Counter Victor V3 (Perkin Elmer, Waltham, USA). Since 
Firefly luciferase reaction is quenched by adding Renilla buffer and luminescence is 
detected at different wavelengths, both luciferases could be detected in one assay. 
 
3.9 Immunohistochemistry and in situ Hybridization 
3.9.1 Frozen Liver Sections 
Sections were prepared in a microtome from frozen organs. Slices (10 µm) were fixed 
with 3 % formaldehyde, while unspecific binding was blocked by incubation with swine 
serum (1:20 dilution, Dako, Glostrup, Denmark) and subsequently stained 
immunohistochemically. 
 
3.9.2 Carnoy Fixation 
Liver tissue was incubated in Carnoy fixative overnight. The fixative was removed by 
overnight incubation in isopropanol followed by embedding of the tissue samples in 
paraffin. 
 
3.9.3 Formalin Fixation 
Liver tissue was fixed in 4 % formalin overnight and washed for 1 h with water. 
Dehydration took place overnight (50-100 % isopropanol) before embedment in 
paraffin. 
 
3.9.4 Preparation 
5 µm sections were performed from Carnoy (3.9.2) and formalin (3.9.3) fixed, paraffin 
embedded tissues. Before staining, slices were deparaffinized in xylene and rehydrated 
(50-100 % ethanol). 
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3.9.5 X-Gal Staining 
Mouse organs were fixed by 2 % paraformaldehyde/ 0.25 % glutaraldehyde in PBS. 
Fixation buffer was removed by washing in 1x PBS for 1 h. β-Galactosidase positive 
cells were stained by an incubation in X-Gal staining buffer at room temperature. 
 
3.9.6 Glucose-6-phosphatase Staining 
Cryo sections were dipped in 0.5% glutaraldehyde in H2Odest and incubated for 20 min 
in the staining solution at 37°C. After short precipitation in 1 % ammonium sulfide, 
they were fixed for 5 min in 5% glutaraldehyde-glacial acetic acid. Sections were 
washed with H2Odest and subsequently stained with Mayer’s haematoxylin for 5 min. 
They were rinsed with water for 15 min and dehydrated in graded alcohols followed by 
repeated incubation in xylene for 5 min and embedment in entellan. 
 
3.9.7 HE Staining 
Cryo sections were washed with H2Odest and subsequently stained with Mayer’s 
haematoxylin for 5 min. They were rinsed with water for 10 min, equilibrated in 50 % 
ethanol for 30 s and stained with alcoholic eosin solution for 3 min. Afterwards, 
ethanol dehydrated the sections followed by repeated incubation in xylene for 5 min 
and embedment in entellan. 
 
3.9.8 Staining of Cyps and GS 
Cryo sections were incubated in methanol/ H2O2 for 15 min to inactivate peroxidases. 
Unspecific binding was blocked before primary antibody binding was performed 
overnight at 4°C in humid atmosphere. Then, horseradish peroxidase conjugated 
secondary antibody was added for 1 h at RT. Sections were stained with 3-amino-9-
ethylcarbazole/ H2O2. 
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3.9.9 Meg3/ Gtl2 in situ Hybridization 
In situ Hybridization (ISH) was performed at the Department for Discovery and 
Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland, 
using the fully automated instrument Ventana Discovery Ultra (Roche Diagnostics, 
Schweiz AG, Rotkreuz, Switzerland) according to Lempiainen et al. 2013. 
 
3.10 Digitonin Based Cell Fractionation 
In order to determine the cellular localization of Gtl2, RNA was fractionated and the 
expression was measured. At once, Histone H3 and GAPDH (glyceraldehyde 3-
phosphate dehydogenase) proteins were used for purity control of the nuclear and 
cytosolic fractions. A well established protein fractionation protocol of Holden et al. 
was adapted to RNA fractionation (Holden and Horton 2009). Thereby, digitonin 
(Sigma, Taufkirchen, Germany) was used to permeabilize the cell membrane, thus 
lysing the cells. 
Cells were scraped off in 1x PBS and pelletized by centrifugation (15 min, 300 g, 4°C). 
The pellet was resuspended in digitonin buffer. After 60 min of incubation at 4°C, 
cytosolic protein fraction was separated by centrifugation (30 min, 2000 g, 4°C). The 
supernatant (cytosolic protein fraction) was divided, half for RNA isolation with TRIzol 
and half for purity control of the cytosolic fraction via western blot. NP-40 buffer was 
used to dissolve the remaining cell pellet and incubated on ice for 45 min. Separation 
of the organelle membrane bound fraction was conducted by centrifugation (30 min, 
7000 g, 4°C). The pellet was dissolved in RIPA buffer containing benzonase and 
incubated on ice for 3 h with recurrent mixing. Nuclear fraction was gained after 
centrifugation (30 min, 7000 g, 4°C) and subsequently divided for RNA and protein 
isolation. 
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3.11 Western Blot  
Polyacrylamide gels are used to separate proteins according to their length and charge. 
Therefore, proteins are denatured with β-mercaptoethanol while SDS imparts a 
negative charge to linearized proteins. 
The running gel was first filled into the assembled chamber and let polymerize covered 
with isopropanol. Then the stacking gel was casted (table 17). 
Table 17: Mix for two SDS polyacrylamide gels 
Reagent 12.5 % running gel 4 % stacking gel 
Acrylamide solution 15 ml 10 ml 
10 % APS 150 µl 100 µl 
TEMED 15 µl 10 µl 
 
Samples were mixed with an equal volume of 2x Lämmli buffer and heated for 10 min 
at 90°C. SDS-PAGE was performed at 100 V to separate proteins. Then, proteins were 
blotted on a PVDF membrane via wet electroblotting at 400 mA and 4°C for 150 min. 
The membrane was dried and activated with methanol. Blocking followed for 1.5 h to 
avoid unspecific binding of the antibodies. The blocking solution was replaced by the 
primary antibody and the membrane incubated overnight at 4°C. The next day, the 
membrane was washed twice before the secondary antibody was added for 2 h. After 
twice washing and incubation with 1x assay buffer, the membrane was covered with 
CDP-Star ready to use (Life technologies, Darmstadt, Germany) and laminated. Photos 
were captured using a CSC Chemoluminescense detection module (Raytest, 
Straubenhardt, Germany) after 1 h incubation in the dark. 
For antibody dilutions, washing and blocking conditions see chapter 2.6. 
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3.12 RNA protein pulldown 
3.12.1 In vitro Transcription 
Linearized plasmid pBlueScript SK(-)/Gtl2-T3 containing Gtl2 DNA flanked of T3 and T7 
RNA polymerase promoters was used as a template for in vitro transcription. The 
following reaction mix (table 18) was incubated at 37°C for 2 h before RNA synthesis 
was stopped by the addition of 2 µl 0.5 M EDTA pH 8.0 and incubation at 65°C for 10 
min. T7 RNA polymerase synthesized Gtl2 in sense orientation, T3 polymerase 
synthesized Gtl2 in antisense orientation. 
Table 18: Reaction mix for in vitro transcription 
Reagent Amount 
5x Transcription buffer 10 µl 
NTPs (10 mM) containing 
Biotin-16-UTP (3.5 mM) 
10 µl 
RNase inhibitor 1.25 µl 
T7 or T3 RNA polymerase 1.5 µl 
Linearized template DNA 1 µg 
DEPC-treated H2O ad 50 µl 
Total volume 50 µl 
 
RNA precipitation took place after adding 4 µl 4 M LiCl and 150 µl EtOH overnight 
at -75°C. RNA was washed with 70 % EtOH and dissolved in DEPC-H2O containing an 
RNase inhibitor. RNA length was determined on an agarose gel, while Biotin 
Luminescent Detection Kit (Roche Diagnostics, Mannheim, Germany) was used to 
detect biotin-labeled nucleic acids by enzyme immunoassay with luminescence 
according to manufacturer’s instruction. 
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3.12.2 RNA Protein Pulldown 
Streptavidin coupled Dynabeads have been extensively used for isolation of 
biotinylated molecules due to their very high binding affinity and the replacement of 
centrifugation by a magnet. Here, Gtl2 binding proteins were isolated and identified 
via mass spectrometry. 
In preparation for the pulldown, Dynabeads M-280 Streptavidin (Life technologies, 
Darmstadt, Germany) were washed twice with 1x BW buffer, solution A and solution B 
before resuspended in 2x BW buffer. The beads were preincubated with 70.4 UT K54 
proteins and washed once again. RNA binding took place by adding 4 µg sense or 
antisense RNA and RNase inhibitor dissolved in the similar volume to that of 2x BW 
buffer and followed by a subsequent incubation on a shaker for 30 min. Unbound RNA 
was washed away three consecutive times with 20 mM Tris-HCl pH 7.5. For protein 
binding, a protein-premix (table 19) was added to the beads dissolved in 1x RNA 
protein binding buffer and incubated for 60 min at 4°C with gentle agitation. 
Table 19: Protein-premix for RNA-protein pulldown 
Reagent Amount 
10x RNA protein binding 
buffer 
10 µl 
Glycerol 15 µl 
Protein (of 70.4 UT K54) 500 µg 
RNase inhibitor  1 µl 
DEPC-treated H2O ad 100 µl 
Total volume 100 µl 
 
Beads had been washed three times with an equal volume of 1x BW buffer. Boiling the 
beads in SDS sample buffer for 15 min eluted bound proteins. Eluate was appended to 
the same amount of water and applied to a SDS-PAGE gel. Bart van den Berg (NMI, 
Protein Analytic, Reutlingen) performed the in-gel digestion and adjacent mass 
spectrometry. A schematic representation of the procedure is given in the figure 
below. 
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Figure 10: Schematic procedure summary for the RNA-protein pulldown using magnetic beads. First, the RNA was 
labeled with biotin and bound to the streptavidin coupled beads. RNA bound beads were then equilibrated in buffer 
before protein mix was added. Unbound proteins were washed away. Samples were eluted by boiling the beads in 
SDS sample buffer. Finally, mass spectrometry was used to identify eluted proteins. This could be determined by 
western blotting (modified after Pierce Magnetic RNA-Protein Pulldown Kit, Thermo Scientific, Schwerte, Germany). 
 
3.13 PET Imaging 
Positron emission tomography (PET) was performed at the laboratory of Prof. Bernd 
Pichler by Dr. Andreas Schmid (Laboratory for Preclinical Imaging and Imaging 
Technology of the Werner Siemens-Foundation, Department of Preclinical Imaging and 
Radiopharmacy, Tübingen) using 18F-FHBG as a reporter probe for imaging thymidine 
kinase 1 reporter gene in the GS mouse. 
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3.14 MRI Imaging 
Magnetic resonance imaging (MRI) was carried out at the laboratory of Prof. Bernd 
Pichler by Dr. Andreas Schmid (Laboratory for Preclinical Imaging and Imaging 
Technology of the Werner Siemens-Foundation, Department of Preclinical Imaging and 
Radiopharmacy, Tübingen) according to Schmid et al. 2013 from week 12 after DEN 
every 2-4 weeks with a 7 Tesla MR scanner (ClinScan, Bruker BioSpin MRI, Ettlingen, 
Germany). 
 
3.15 Statistic data processing 
Statistic processing of the datasets including mean value, standard deviation and 
standard error of mean were conducted in excel. Two groups were compared using the 
paired or unpaired student’s t-test. Differences were considered significant in groups 
with five or more independent experiments or animals when p < 0.05 (indicated by *). 
P < 0.01 is indicated by **, p < 0.001 by ***. 
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4. Results 
4.1 Gtl2 Expression in Different Tumor Tissues 
4.1.1 Expression of Gtl2 Transcript Variant 3 in Murine Liver 
Recent work of our MARCAR project partners showed that several non-coding RNAs 
encoded in the imprinted Dlk1-Dio3 gene cluster are upregulated in wild type mouse 
liver after PB treatment (Lempiainen et al. 2013, Phillips et al. 2009). Long non-coding 
RNA Gtl2, the human orthologue is known as MEG3 (maternally expressed gene 3), is 
the main topic in this thesis and located within this cluster. 
Three Gtl2 transcript variants of varying length were documented in the NCBI 
database, but only transcript variant 3 (NR_027652.1), the shortest one with 1.9 kb, 
could be detected in the above mentioned PB promoted liver tumors and in PB treated 
normal liver (figure 11). Thus, Gtl2 transcript variant 3 (Gtl2-T3) expression was 
determined from now on, in the following only named Gtl2. 
 
                 
 
 
 
 
Figure 11: Gtl2 transcript variants expressed in murine tissue. (A) Three different Gtl2 transcript variants of varying 
length are documented in the NCBI database, (B) but only Gtl2 transcript 3 (NR_027652.1, Gtl2-T3) could be 
detected in phenobarbital (PB)-treated normal liver (NL) and Ctnnb1 mutated tumor tissue (T). M, marker. 
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As recapitulated in figure 12, Gtl2 expression was upregulated both in normal murine 
liver after PB treatment and in Ctnnb1 mutated liver tumors compared to untreated 
controls, although the increase was much higher in Ctnnb1 mutated tumors. Ras/ Raf 
mutated liver tumors showed a decrease in Gtl2 expression compared to Ctnnb1 
mutated tumors. 
 
Figure 12: Relative Gtl2 expression in normal liver (NL) compared to phenobarbital treated liver (NL + PB) for 12 
weeks, Ctnnb1 mutated tumor and Ras/ Raf mutated tumor tissue. Gtl2 was upregulated after phenobarbital (PB) 
treatment, in Ctnnb1 mutated liver tumors, but downregulated in Ras/ Raf mutated tumors. PB treatment is 
indicated by hatching. n=3-5, ±SEM are given. 
 
4.1.2 Induction of Gtl2/ MEG3 Expression in Human, Mouse and Rat Liver 
To check the transferability to other species with tumors comprising Ctnnb1 
mutations, MEG3 expression was ascertained in human hepatoblastoma (HB), a rare 
liver neoplasm occurring in small infants and children. Samples were obtained from 
the University Children’s Hospital, Tübingen. Recent analysis by Dr. Andreas Schmidt 
demonstrated 80 % prevalence of mutations in CTNNB1 in those tumor samples 
(Schmidt et al. 2011). Only tumor samples comprising these mutations were used for 
the following measurement. As shown in figure 13, MEG3 was elevated in most 
CTNNB1 mutated hepatoblastoma samples compared to adjacent normal liver tissue. 
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Figure 13: Relative MEG3 expression in CTNNB1 mutated human hepatoblastoma compared to normal tissue. 
Tumors were represented by grey bars, normal tissue by colorless bars. MEG3 was upregulated in most mutated 
hepatoblastoma. Presented data result from three measurements; mean ±SEM are given. NG, normal liver 
surrounding the respective tumor; HB, hepatoblastoma. 
 
Lempiainen et al. 2013 revealed altered gene expression in the whole Dlk1-Dio3 cluster 
in Ctnnb1 mutated liver tumors growing under PB treatment. As evident from 
figure 12, Gtl2 expression was reduced in Ras/ Raf mutated liver tumors compared to 
those tumors harboring a Ctnnb1 mutation, selected by the tumor promoter PB. To 
clarify whether PB treatment of mice would lead to a reexpression of Gtl2 in Ras and 
Raf mutated liver tumors, mice that had been treated at 2 weeks of age with DEN were 
treated with PB for 4 weeks at the age of 6 months, when Ras/ Raf mutated tumors 
were expected to be manifest. Interestingly, in response to PB, Ras and Raf mutated 
tumors expressed significantly less Gtl2 and expression of Rian and Mirg, two other 
non-coding RNAs from the maternal allele, was also downregulated. These changes 
were accompanied by decreased mRNA levels of two protein coding genes on the 
cluster, Rtl1 and Dio3, as it is depicted in figure 14. Dlk1 could not be detected. These 
result also clearly shows that PB alone cannot explain the upregulation of Gtl2 in 
Ctnnb1 mutated liver tumors since such an effect was not seen in their Ras/ Raf 
mutated counterparts. 
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Figure 14: Relative expression of Dlk1-Dio3 cluster genes in murine Ras or Raf mutated tumors treated with or 
without phenobarbital. The maternal genes Gtl2, Rian and Mirg, represented by dark grey bars, were 
downregulated in Ras/ Raf tumors of animals treated with phenobarbital (PB) for 4 weeks at the age of 6 months as 
well as the paternal genes Rtl1 and Dio3, represented by light grey bars. PB treatment is indicated by hatching. 5-6 
animals per group; mean ±SEM are given. Unpaired student’s t-test *… p-value < 0.05. 
In the following, Dlk1-Dio3 cluster alterations were examined administrating additional 
NGC to mice to decide whether the foregoing observed perturbations were 
attributable only to PB or also to other NGC. In a previous study, equipotent doses of 
the polychlorinated biphenyls PCB 153 and PCB 126, and a combination of both were 
administered to mice for 22 weeks. PCB 153 is a prototype PB-like PCB acting through 
CAR while PCB 126 is a dioxin-like PCB which acts via the Ah-receptor. Because recent 
studies had shown that the potency of PCBs are correlated to their Cyp inducing 
capacity, induction of Cyp2b10 and Cyp1a1 isoforms respectively were used as an 
indicator of their outcome, as indicated in figure 15. In response to PCB 153 and 
PCB 126, hepatocytes expressed significantly higher levels of maternally expressed 
Gtl2, Mirg and Rian and the paternal Rtl1, while the other paternal protein coding gene 
Dio3 was downregulated. Once again, Dlk1 could not be detected. 
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Figure 15: Relative expression of Dlk1-Dio3 cluster genes and Cyp2b10 and Cyp1a1 in murine liver treated with 
PCB 153, PCB 126 or a combination of both for 22 weeks. The aryl hydrocarbon receptor (AhR) agonist PCB 126 and 
PCB 153, acting via activation of the constitutive androstane receptor (CAR) led to enhanced Gtl2, Mirg and Rtl1 
expression. The corresponding Cyp isoform was also upregulated. Paternal gene Rtl1 was upregulated but Dio3 was 
downregulated. Maternal genes are represented by dark grey bars, while paternal genes are represented by light 
grey bars. PCB treatments are indicated by different hatching. 5 animals per group; mean ±SEM are given. Unpaired 
student’s t-test *… p-value <0.05, ** < 0.01, *** < 0.001. 
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Since PB is a non-genotoxic hepatocarcinogen in rodents (Lee 2000, Whysner et al. 
1996), there is toxicological concern about the relevance of this effect for humans. In 
this case, the development of humanized mouse models provides a powerful approach 
for understanding pathways of human diseases. To analyze potential species 
differences in receptor dependent Dlk1-Dio3 cluster regulation underlying liver tissue 
molecular responses to other CAR activators to which man may be exposed, 
humanized CAR/ PXR (hCAR/ hPXR) and wt mice obtained two different doses of 
cyproconazole (cypro) or prochloraz (procl) in the diet for 4 weeks. Both compounds 
are part of the conazole fungicides with cypro belonging to the larger group of triazol 
fungicides while procl is characterized by the presence of an imidazole ring and is thus 
member of the imidazole fungicides. Samples were available from a recently 
conducted study in our lab (Braeuning, unpublished). 
Induction of Cyp2b10 expression was used, as in the PCB-study, as an indicator of CAR 
activation caused by the fungicides cyproconazole and prochloraz. Analogous to other 
CAR agonists, cypro induced mRNA levels of all three lncRNAs, namely Gtl2, Rian and 
Mirg quite differently in a concentration dependent manner. Surprisingly, the highest 
concentration was less effective in altering their expression than the lower one. As 
illustrated in figure 16, procl had the ability to augment maternal Gtl2, Rian and Mirg 
expression, too, while in contrast, paternal protein coding genes Rtl1 and Dio3 showed 
extenuated expression levels after treatment with both fungicides. Upon comparison 
of wt with humanized mice, the latter displayed a fewer impact of procl and cypro on 
all maternal Dlk1-Dio3 cluster genes above mentioned, while paternal genes were 
downregulated to an equal or even greater extent. 
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Figure 16: Relative expression of Dlk1-Dio3 cluster genes and Cyp2b10 in the liver of wt and hCAR/ hPXR animals 
treated with different concentrations of two fungicides, cyproconazole (cypro) and prochloraz (procl) for 4 weeks. 
Paternal protein coding genes Rtl1 and Dio3 were downregulated, while the maternal Gtl2 was upregulated. The 
other two maternal genes, Rian and Mirg showed a varying expression. Cyp2b10 was upregulated. Maternal genes 
are represented by dark grey bars, while paternal genes are represented by light grey bars. Conazole fungicide 
treatments are indicated by different hatching. 6 animals per group; mean ±SEM are given. Unpaired student’s 
t-test *… p-value < 0.05, ** < 0.01, *** < 0.001. 
 
At present, most toxicological studies and long term experiments are performed in 
rodents, often mice, but more frequently in rats as they pose a more transferrable 
model to humans. Therefore, analysis of liver samples of Wistar rats fed with PB and 
clofibrate (CF) were included in this work. As already described by Ittrich et al. 2003, 
male and female rats developed preneoplastic foci of altered hepatocytes when 
feeding them with the mentioned NGC (0.05 % PB or 0.5 % CF) for 10 consecutive 
weeks. Augmented Cyp2b10 expression could be regarded as the indicator for CAR 
activation whilst Cyp4a posed as a marker for peroxisome proliferation (figure 18). As 
it is depicted in figure 17, CF and PB were able to influence Gtl2 expression in male and 
female rats only very moderately without statistical significance. These findings of NGC 
action were compared to GC effects caused by N-nitrosomorpholine (NNM) and 
2-acetlyaminofluorene (AAF). NNM diminished Gtl2 level in both genders, but AAF 
revealed significant gender differences (figure 17). Interestingly, AAF induced Gtl2 
expression in liver of males which also were much more sensitive to the aromatic 
amine with respect to the development of preneoplastic foci while no such effect were 
seen in the comparatively insensitive females (Ittrich et al. 2003). 
Hereinafter, expression of Wnt target genes was monitored by qPCR. All treated rats 
displayed homogenous augmented Cyp7a1 expression in their livers. The enzyme 
catalyzes the rate limiting step of bile acid synthesis from cholesterol. Serine 
dehydratase (Sds), converting serine into pyruvate, and glutaminase 2 (Gls2), an 
isoform of glutaminase normally expressed in kidney, were said to be downregulated 
in Ctnnb1 mutated mouse liver tumors (Unterberger et al. 2014). In rat liver foci, Sds 
and Gls2 mRNA levels were upregulated after PB and CF treatment and downregulated 
after AAF treatment as illustrated in figure 18. NNM, however, showed an inverted 
pattern of Sds and Gls2 expression in male and female Wistar rats. 
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Figure 17: Relative Gtl2, Gls2 and Sds expression in liver tissue from rats treated with NGC (PB, CF) or GC (NNM, 
AAF) for 10 consecutive weeks. 0.05 % phenobarbital (PB) and 0.5 % clofibrate (CF) treatment induced Gtl2 
expression in both genders, but only moderate without any significance, while NNM (N-nitrosomorpholine, 5 mg/kg 
bwt) led to a downregulation. Gtl2 showed a gender specific different expression after AAF (2-acetlyaminofluorene, 
10 mg/kg bwt) treatment. Gls2 and Sds, known to be negative Wnt target genes, were expressed diverse concerning 
to NGC and GC treatment. Sds was upregulated after PB and CF, but downregulated after NNM and AAF treatment. 
Gls2 shows various expressions. Treatment groups are indicated by different hatching. 4-5 animals per group; mean 
±SEM are given. Unpaired student’s t-test *… p-value < 0.05, *** < 0.001. 
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Figure 18: Relative Cyp expression in liver tissue from rats treated with NGC (PB, CF) or GC (NNM, AAF) for 10 
consecutive weeks. 0.05 % phenobarbital (PB) and 0.5 % clofibrate (CF) treatment were used to induce Cyp2b10 or 
Cyp4a expression. Cyp7a1, known to be upregulated with active β-catenin signaling, was also upregulated under PB 
and CF treatment, as well as after administration of the two GC NNM (N-nitrosomorpholine, 5 mg/kg bwt) and AAF 
(2-acetlyaminofluorene, 10 mg/kg bwt). Treatment groups are indicated by different hatching. 4-5 animals per 
group; mean ±SEM are given. Unpaired student’s t-test *… p-value < 0.05, ** < 0.01, *** < 0.001. 
 
4.1.3 Gtl2 Expression in Murine Primary Hepatocytes 
One of the aims of modern toxicology is to reduce, refine and replace experimental 
animal use. For this reason, further experiments on Gtl2 were carried out with cultures 
of freshly isolated hepatocytes. Primary hepatocytes are frequently used in vitro 
models for investigating drug metabolism and signaling pathways (Klingmuller et al. 
2006). Dissected hepatocytes were grown on collagenase coated plates and treated for 
24 h and 48 h with PB to activate CAR dependent gene expression. As illustrated in 
figure 19, Cyp2b10 expression, as an indicator for CAR activation, was elevated after 
24 h of treatment but returned to nearly basal level at the later time point of 
investigation. Gtl2 levels were unchanged at all time points studied. 
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Thus, primary hepatocytes do not serve as an adequate system for investigating Gtl2 
targets and Gtl2 regulation. 
 
Figure 19: Relative Cyp2b10 (A) and Gtl2 (B) expression in primary hepatocytes treated with or without 3 mM 
phenobarbital for 24 h and 48 h. Cyp2b10 levels were upregulated after 24 h of phenobarbital (PB) treatment, 
while no effects on Gtl2 expression were visible. PB treatment is indicated by hatched bars. n=2; mean ±SD are 
given. 
 
4.1.4 Gtl2/ MEG3 Expression in Hepatoma Cell Lines 
Cell lines with hepatic characteristics have been isolated from mouse liver tumors 
(Kress et al. 1992, Bernhard et al. 1973). The hepatocellular cell lines 70.4, 53.2b, 55.1c 
and Hepa1c1c.7 employed in this work were characterized in terms of mutations in the 
Ctnnb1, Ha-ras and B-raf proto-oncogenes by former group members as previously 
described (Aydinlik et al. 2001, Jaworski et al. 2005). 
Unfortunately, expression of Gtl2 could not be detected in any of the various cell lines 
investigated, which were derived from liver tumors of C57BL/6 or C3H/ He mice or 
from man (not shown). Surprisingly, a recently published pediatric human 
hepatocellular cell line, named HC-AFW1, showed MEG3 expression accompanied by 
strong β-Catenin expression (figure 20). This cell line shows a deletion of 49 bp in exon 
3 of CTNNB1 (Armeanu-Ebinger et al. 2012). These cells are special as they express CAR 
receptor (figure 20 A) what few cell lines do. 
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Figure 20: (A) CAR and β-Catenin
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 expression and (B) MEG3 expression in human HC-AFW1 cell line.
 be possible to manipulate MEG3 expression
to be tested. 
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4.1.5 CAR Regulation of Gtl2 Upstream Regions 
Since it is known that both β-catenin signaling and CAR receptor are necessary for a 
stable Gtl2 expression (Lempiainen et al. 2013), Gtl2 reporter vectors were created 
and transfected in a murine hepatoma cell line harboring physiologically activated 
β-catenin and conditionally expressed CAR receptor. Gtl2 reporter vectors were 
constructed containing 5’ upstream sequences of the transcription start of the 3 
different transcripts according to the NCBI database. Transcript 1 (T1) transcription 
start was more downstream than the starting point of transcripts 2 and 3 (T2_3). For 
illustration of the upstream regions, see figure 22. 
Four reporter vectors were generated: Prom_T1 spanning 1.3 kb before T1, and 
Prom_T2_3, subdivided into Prom_T2_3_A (beginning), Prom_T2_3_M (middle) and 
Prom_T2_3_E (end), together nearly 5 kb. T2_3 upstream region had been chosen 
larger, given that T3 was the detected transcript variant at mRNA level (figure 11). 
 
Figure 22: Schematic representation (not at scale) of murine Gtl2 upstream regions. Indicated sequences were 
cloned into pT81luc to analyze CAR dependent regulation of these sequences. Different parts of Gtl2 upstream 
regions were indicated by different colors. 
These reporters were, together with an expression vector for CAR, co-transfected into 
55.1c mouse hepatoma cells, a cell system that had already been used successfully in 
recent promoter studies (Loeppen et al. 2005). At 24 h after transfection, the Prom_T1 
reporter construct responded to the co-transfected CAR expression vector with an 
approximately 3.6 fold induction of luciferase activity, as it is depicted in figure 23. 
Prom_T2_3_E and A showed a significant difference in CAR response, but these effects 
were very low. Contrastingly, β-catenin-mediated induction of luciferase activity failed 
in all reporter constructs (not shown). 
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Figure 23: Relative activity of the four Gtl2 reporter vectors in 55.1c mouse hepatoma cells, as determined by 
firefly luciferase measurement. Cells were co-transfected with CAR (constitutive androstane receptor) for 24 h. 
Gtl2 transcript 1 promoter activity was upregulated by cotransfection of CAR, while transcript 2/3 promoters 
showed a significant difference in CAR response, but these effects were very low. Presented data result from five 
independent experiments performed in quadruplicates; mean ±SEM are given. Unpaired student’s t-test * … p-value 
< 0.05, ** < 0.01. 
 
4.1.6 Role of Gtl2 in β-Catenin Signaling Regulation 
β-Catenin signaling plays a crucial role in proliferation of cancer cells and is often 
deregulated in these cells. To identify a possible participation of Gtl2 in Wnt/ β-catenin 
signaling, a vector has been created constitutively expressing Gtl2 under the control of 
a CMV promoter. Through transfection of murine hepatoma cells with this construct, 
Gtl2 got transiently expressed. Mouse hepatoma cells containing a 7x TCF/ LEF driven 
luciferase vector (SuperTopflash; STF) stably or transiently expressed were co-
transfected with the Gtl2 construct or the corresponding empty vector and treated 
either with LiCl, to activate β-catenin signaling, or NaCl as a control, respectively. 
Firefly luciferase activity was measured and normalized to Renilla. β-Catenin 
dependent luciferase activity was increased upon activation of Wnt signaling, and even 
more increased under the influence of Gtl2, indicating a connection between β-catenin 
signaling and Gtl2 expression (figure 24). This correlation could not be substantiated, 
however, on the mRNA level (not shown). 
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Figure 24: Activation of a β-catenin dependent TCF/ LEF driven reporter vector in different mouse hepatoma cell 
lines. (A) 70.4 K15 cells stably transfected with a 7x TCF/ LEF driven luciferase vector (SuperTopflash; STF) were 
transiently transfected with Gtl2 (grey bars) or the empty vector (unfilled bars) and treated with 15 mM NaCl or 
15 mM LiCl (hatched bars) for 24 h. Firefly luciferase activity was normalized to Renilla. n=5. (B) 53.2b cells 
transiently transfected with STF and additional Gtl2 (grey bars) or the empty vector (unfilled bars) and treated with 
15 mM NaCl or 15 mM LiCl (hatched bars) for 24 h. Firefly luciferase activity was normalized to Renilla. n=5, mean 
±SEM are given. Paired student’s t-test * … p-value < 0.05, the respective bars are indicated with lines above. 
To improve standardization and reproducibility, two additional Gtl2 expression 
systems have then be established and tested. 
 
4.2 Generation and Characterization of Engineered Gtl2 Expressing Cell 
Lines 
A way of overexpressing a gene is its delivery by an adenovirus. Recombinant 
adenovirus vectors delete genes from the wt adenovirus, making a replication 
impossible and the system safe for use. Due to its high transduction efficiency and high 
expression level, adenovirus vectors have been widely used for transduction 
experiments. In cooperation with Michael McMahon, University of Dundee, Scotland, a 
Gtl2 expressing adenoviral construct has been generated and successfully introduced 
into Hepa1c1c.7 mouse hepatoma cells. The amount of adenoviruses used is expressed 
by the multiplicity of infection (MOI). MOI is the ratio of the number of virus particles 
to the number of target cells. As visualized in figure 25 A, Gtl2 was expressed MOI 
dependent, 100 MOI showing a ten time greater expression than 10 MOI. Transient 
expression, not integrating the DNA into the nuclear genome, has the disadvantage 
that a variable number of cells are transfected in each passage, resulting in divergent 
measurement values. If it is desired that the transfected gene actually remains in the 
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genome of the cell and its descendants and therefore reaching cellular homogeneity, a 
stable transfection must be achieved. 
Clontechs Tet-On Advanced Inducible Gene Expression System is a tightly regulated 
system that produces by request expression of a gene of interest in target cells. The 
system was established in 70.4 mouse hepatoma cells by sequentially transfecting 
them with a Tet-On Advanced transactivator and a vector containing Gtl2 under the 
control of a PTight inducible promoter and selecting a stable cell line. Target cells 
expressed high levels of Gtl2 when cultured in the presence of the system’s inducer 
doxycycline in a dose dependent manner, as shown in figure 25 B. Cells were termed 
70.4 UT K54. 
 
Figure 25: Two mouse hepatoma cell culture systems with induced Gtl2 expression. (A) Hepa1c1c.7 cells were 
transduced with 10 or 100 MOI of an adenoviral Gtl2 vector for 24 h to express Gtl2, n=3, mean ±SD are given. 
(B) 70.4 UT K54 cells stably transfected with a Gtl2 vector were treated with 0.1 µg/ml and 1 µg/ml doxycycline 
(dox) for 24 h to turn on Gtl2 expression, n=5, mean ±SEM are given. Paired student’s t-test *… p-value < 0.05, 
** < 0.01. 
Two systems expressing Gtl2 had been generated as described above. For further 
studies, substantiation of the physiological location of long non-coding RNA Gtl2 was 
inevitable. Physiologically, Gtl2 was more abundant in the nucleus of mouse 
hepatocytes (figure 26 B). Therefore, in situ hybridization experiments were carried 
out in the laboratory of Valérie Dubost at the Novartis Institutes for Biomedical 
Research, Basel. The experiments were conducted in fixed and paraffin embedded 
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murine liver tissue. To examine the intracellular localization of Gtl2 in 70.4 UT K54 
cells, digitonin based cell fractionation was performed in doxycycline treated (24 h) or 
untreated cells. The results demonstrated that the majority of the transcript was 
located in the nucleus, hence in analogy to the physiological situation in vivo. GAPDH 
and Histone H3 proteins served as controls for cytoplasmic and nuclear fractions, 
respectively (figure 26 A). 
 
Figure 26: Nuclear localization of Gtl2 in vitro and in vivo. (A) Digitonin based cell fractionation with 70.4 UT K54 
cells after doxycycline treatment for 24 h, where GAPDH and Histone H3 (His H3) served as controls for cytoplasmic 
(C) and nuclear (N) fraction, respectively; and (B) Gtl2 ISH in normal murine liver showed that Gtl2 was more 
abundant in the nucleus. n=3, one representative experiment is given. 
After having demonstrated that Gtl2 shows nuclear localization in 70.4 UT K54 cells, 
the cells were then used to search for potential Gtl2 targets on both RNA and protein 
level. The RNA expression patterns of engineered Gtl2 expressing cells were analyzed 
by use of the Affymetrix GeneChip Mouse Gene 2.1 ST Array which contains 
approximately 35,240 probe sets, including more than 26,000 well established mouse 
genes and more than 3,300 non-coding transcripts. Genes were selected with 
minimum 50 % deregulation. These cutoffs were chosen to minimize false positive 
results of genes identified as being differentially regulated. In total, 211 genes were 
identified that were variably expressed. Under these genes were a striking number of 
immunglobuline J genes, olfactory receptors (Olfr), and non-coding RNAs like miRNA, 
snoRNA and snRNA. The gene distribution of 50 % deregulated genes is visualized in 
figure 27. In contrast, protein coding genes were underrepresented (table 20). 
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Figure 27: Gene distribution of 50 % deregulated genes in UT K54 cells (doxycycline vs. without doxycycline). 
Many non-coding RNAs were deregulated, olfactory receptors and immune genes were additionally clustered, small 
RNAs not. 
 
Table 20: Affymetrix analysis with group enrichment in 70.4 UT K54 (doxycycline vs. without doxycycline). Protein 
coding genes were underrepresented, IG_J, miRNAs, snoRNAs and snRNAs were overrepresented. 
# transcript_type total_count diff_count p.over p.under 
1 antisense 1097 4 1 0.61 
2 IG_C_gene 12 0 1 0 
3 IG_D_gene 4 1 0.33 1 
4 IG_J_gene 83 6 0.0003 1 
5 IG_V_gene 346 5 0.90 1 
6 lincRNA 1110 3 1 0.21 
7 miRNA 347 17 5.11 E-09 1 
8 misc_RNA 444 7 0.37 1 
9 polymorphic_pseudogene 8 0 1 0 
10 processed_transcript 184 3 1 1 
11 protein_coding 23126 108 1 2.29 E-14 
12 pseudogene 270 1 1 1 
13 rRNA 279 2 1 1 
14 sense_intronic 72 0 1 0 
15 snoRNA 1185 22 0.0003 1 
16 snRNA 1123 24 1.28 E-05 1 
 
 
 
10 
12 
15 
23 
22 
119 
3 
7 
Results Page 82 
A heatmap showing the most deregulated genes in 70.4 UT K54 cells with Gtl2 
compared to the same cells without Gtl2 is illustrated in figure 28. 
 
Figure 28: Heatmap showing the 30 most deregulated genes in 70.4 UT K54 cells with Gtl2 compared to the same 
cells without Gtl2. 
 
To validate the microarray data, expression of several of the deregulated genes was 
additionally analyzed by qPCR. However, the PCR data did not resemble the findings of 
the microarray analysis. Either no differences were visible or as in the case of Olfr612, 
Olfr495, Oaz1 and Wdr20a, the corresponding RNA could not be detected (not shown). 
 
Gtl2 target search was also performed on protein level. Magnetic RNA protein 
pulldown provides an efficient way of isolating proteins bound to the bait RNA. In this 
case, Gtl2 RNA was in vitro transcribed, biotin labeled and used to capture Gtl2 binding 
proteins via streptavidin magnetic beads. Washing fractions 1 and 3 as well as the 
eluted protein fraction were separated according to weight as indicated in figure 29. 
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Figure 29: Output of the RNA-protein pulldown assay. (A) sense Gtl2-RNA: Lane 1: M, marker; lanes 2, 3: W, 
washing fractions 1, 3; lane 4: E, eluate. (B) antisense Gtl2-RNA: Lane 1: M, marker; lane 3: E, eluate; lanes 4,5: W, 
washing fractions 3, 1. 
 
Bart van den Berg, NMI, Natural and Medical Sciences Institute at the University of 
Tübingen, carried out the in gel digestion, mass spectrometry and data analysis to 
identify Gtl2 binding proteins. A striking number of ribosomal proteins were detected, 
but known proteins with Gtl2 interaction like JARID, part of the PRC2 complex (Kaneko 
et al. 2014), were missing. 
 
4.3 Adenoviral Overexpression of Gtl2 in vivo 
Cell culture results were not viewed as sufficient for identifying cellular or biochemical 
consequences resulting from Gtl2 overexpression. Despite the effort to work with non-
animal alternatives, mice offer a more realistic system to study liver functions. 
 
4.3.1 Determination of Gtl2 Expression after Adenoviral Transduction in vivo 
Gtl2 containing adenoviral constructs were already successfully tested in cell culture to 
conditionally overexpress Gtl2. Thus, these viral particles were virtually predestined to 
introduce Gtl2 into murine liver. After injection into the tail vein, particles migrate with 
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the blood flow into the liver lobule, entering via the portal vein. To prove increased 
Gtl2 expression, mice were sacrificed 4 or 8 days after injection. The liver was cut out 
and Gtl2 in situ hybridization using DIG-labeled single stranded riboprobes targeting a 
conserved 500 bp region in the Gtl2 transcript was carried out to localize Gtl2 in 
adenoviral treated liver sections in the laboratory of Valérie Dubost, Novartis Institutes 
for Biomedical Research, Basel. The experiments were conducted in fixed and paraffin 
embedded liver tissue. Physiologically, Gtl2 expressing nuclei surrounded the central 
vein (blue arrow) as it is depicted in figure 30 A, B. Four days after adenoviral Gtl2 
transduction (figure 30 C, D), Gtl2 was additionally expressed in hepatocytes far away 
from the central vein (red arrow) in large quantities. The Gtl2 transcript was more 
abundant in the nuclei, as it is physiologically. Adenoviral Gtl2 expression disappeared, 
however, at day 8 (figure 30 E, F) and returned to a physiological level. 
 
 
A B 
C D 
Results Page 85 
 
Figure 30: Gtl2 ISH in adenoviral treated murine liver. (A, B) Control, (C, D) Gtl2 4d and (E, F) Gtl2 8d animals are 
shown. Physiologically, Gtl2 was expressed around the central vein (blue arrows), but after adenoviral Gtl2 
transduction, it was also expressed far away from the central vein (red arrow). Adenoviral Gtl2 expression 
disappeared till day 8. Pictures were taken with 5x (left) and 20x (right) magnification at Novartis, Basel.  
In order to confirm elevated Gtl2 expression 4 days after adenoviral transduction, 
mRNA levels were analyzed, too. At the 4-day time point, Gtl2 RNA was clearly 
enhanced in liver. Control mice, which only received a GFP containing vector, remained 
at basal level. Animals that had received the Gtl2 vector returned to the physiological 
pattern 8 days after transduction (figure 31). 
 
Figure 31: Relative Gtl2 expression in adenoviral treated mice. Control animals received a GFP vector, Gtl2 animals 
received a Gtl2 containing vector (hatched bars). Animals were killed 4 days or 8 days after injection. 3 animals per 
group, 3 samples per animal, mean ±SEM are given. 
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4.3.2 Phenotype of Gtl2 Transduced Murine Liver 
To uncover a potential phenotype change mediated by Gtl2 overexpression, Carnoy 
fixed liver slices were stained for glutamine synthetase (GS), Cyp1a2 and Cyp2b. 
Glutamine synthetase was chosen because reporter gene experiments indicated a 
connection between β-catenin signaling and Gtl2 expression. GS is also the most 
prominent marker for perivenous hepatocytes and β-catenin overexpression, since a 
direct correlation has been demonstrated in mouse liver tumors (Loeppen et al. 2002). 
Cyp1a2 is a representative enzyme of phase I metabolism, preferentially expressed in 
the perivenous zone of the liver, too. Cyp2b is a known target of PB mediated CAR 
activation (Honkakoski et al. 1998). 
Immunohistochemical analyses of liver sections from adenoviral treated mice were 
performed, which demonstrated a perivenous expression of GS accompanied by 
Cyp1a2 expression in the same areas, prevailing the classic picture of zonation in the 
liver lobule. No difference between Gtl2 and control group could be detected, neither 
after 4 days (figure 32) nor after 8 days (not shown). Cyp2b, representing the PB like 
phenotype, was also unaffected by Gtl2 (figure 32). 
 
 
Figure 32: Immunostaining of Gtl2 treated vs. control mice. There is no difference between Gtl2 and control 
animals in perivenous glutamine synthetase (GS), Cyp1a2 and Cyp2b expression. Pictures were taken with 20x 
magnification, representative of n=3. 
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By having a closer look on the cell morphology visualized by haematoxylin and eosin 
(HE) stain, some apoptotic cells could be seen in the Gtl2 group as well as in the 
control group after 8 days. Additionally, 8 days of adenoviral exposure led to clustered 
small foci of inflammation (figure 33). 
 
Figure 33: HE-staining of Gtl2 treated vs. control mice. Adenoviral gene transfer led to some apoptotic cells (blue 
arrow) and foci of inflammation (red arrow) after 8 days of adenoviral exposure to Gtl2 and GFP (control). Pictures 
were taken with 20x and 40x magnification, representative of n=3. 
 
4.3.3 Quantification of Dlk1-Dio3 Cluster Genes 
Gtl2 is located on one of the largest imprinting gene clusters close to other imprinted 
genes deregulated upon NGC treatment in mice. Since it is known that Dlk1 is directly 
regulated by Gtl2 (Zhao et al. 2010), a correlation between Gtl2 expression and 
expression of other genes on the same cluster would be conceivable. 
Since the Gtl2 level was only increased after 4 days of transduction, 8 day samples 
were disregarded. Relative expression of Dlk1-Dio3 cluster genes is illustrated in 
figure 34. Maternally expressed Rian and Mirg were only slightly upregulated in 
parallel to Gtl2 overexpression. In contrast to the findings with CAR activation in vivo, 
paternal Rtl1 and Dio3 revealed an induction, too. Large standard deviations were 
obtained due to small sized animal groups and differences between animal responses. 
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Figure 34: Relative expression of Dlk1-Dio3 cluster genes in adenoviral treated mice. Control animals received a 
GFP vector, Gtl2 animals received a Gtl2 containing vector (hatched bars). Animals were killed 4 days after injection. 
3 animals per group, 2 groups; mean ±SEM are given. 
 
4.3.4 Effects of Gtl2 Overexpression on Proliferation 
In contrast to normal cells, which only divide a restricted number of times before 
entering into growth arrest, cancer cells never cease to proliferate. The loss of 
negative cell cycle control can promote tumorigenesis. Due to the fact that Gtl2 was 
postulated as a potential tumor marker, Gtl2 might directly or indirectly affect cell 
proliferation. Two key classes of regulatory proteins, cyclins and cyclin dependent 
kinases (Cdks) determine the cell cycle (Nigg 1995). Cdks are among the most 
important and phosphorylate their substrate. As their name says, they require the 
presence of cyclins to be active. 
Cyclin D1 (Ccnd1) expression was downregulated upon Gtl2 overexpression in murine 
liver, just as Cdk2 and Cdk4. Similarly, proliferating nuclear antigen (Pcna), which is 
essential for replication by forming a DNA clamp and encircling the DNA, augmenting 
DNA polymerase’s processivity, was downregulated, too (figure 35). 
Summarizing the above, it appears that cell cycle activity was decreased by Gtl2 
overexpression in murine hepatocytes. 
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Figure 35: Relative Cyclin D1, Cdk2, Cdk4 and Pcna expression in adenoviral treated mice. Control animals 
received a GFP vector, Gtl2 animals received a Gtl2 containing vector (hatched bars). Animals were killed 4 days 
after injection. 3 animals per group, 2 groups; mean ±SEM are given. Cell proliferation genes were downregulated in 
the presence of Gtl2. Ccnd1, Cyclin D1; Cdk2, Cyclin dependent kinase 2; Cdk4, Cyclin dependent kinase 4; Pcna, 
proliferating cell nuclear antigen. 
 
4.4 GS Reporter Mouse 
The second main topic of this work is a specific reporter mouse, harboring 3 different 
reporters, namely FLuc, LacZ and Tk-1, under the control of the glutamine synthetase 
promoter. As GS is a target for β-catenin signaling, this promoter is specifically 
activated in tissues, where β-catenin dependent signaling is active, as for example in 
perivenous hepatocytes and in Ctnnb1 mutated liver tumors. 
Transgenic GS reporter mice were born at the expected ratio of ∼50 % after 
interbreeding Taconic GS-2A-LacZ-2A-Tk-1-2A-FLuc multi reporter model mice with 
mice of strain C3H/ He N. PCR analysis was performed to detect germline transmission 
of wt and konst Ki locus in GS mice (figure 36). 
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Figure 36: PCR analysis to detect germline transmission of wt and konst Ki locus in GS mice: DNA isolated from GS 
mice progeny was analyzed via PCR with primers 7656_68 and 7656_69. Mice harboring the GS transgene (konst Ki) 
were detected by the presence of an additional PCR fragment of 403 bp (indicated by the black arrow). M, marker;  
-, wt; +, Ki; w, negative probe; pos, positive probe. 
 
4.4.1 Preliminary Testing of Reporter Genes in GS Mice 
The functionality of the Firefly luciferase reporter (FLuc) was investigated first. Male GS 
mice and their wt littermates were used to generate homogenates of different organs, 
including heart, liver, kidney, lung and gut. Luciferase activity was first determined in 
heart homogenate using serial dilutions and a firefly luciferase inhibitor to quench 
luciferase activity. In comparison, activity of the recombinant enzyme was measured. 
As shown in figure 37, luciferase activity in the GS mice was clearly dependent on 
homogenate concentration and could be repressed by the enzyme inhibitor, 
demonstrating the specificity of the assay system. 
Additionally, the assay was calibrated with recombinant luciferase to allow an 
estimation of the amount of enzyme per tissue unit.  
M       -          +         +         -       -         -         +         -         +         +        +        +        +        -         +        -         w       pos.  
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Figure 37: Firefly luciferase activity in the heart of the GS reporter mouse. Several dilutions of heart homogenate 
were used for determining firefly luciferase activity. A luciferase inhibitor attenuated luciferase activity, 
recombinant enzyme is shown for comparison; n=3 animals, mean ±SD are given. 
Firefly luciferase to tissue ratio is depicted in figure 38. GS mice showed a strong 
luciferase signal compared to the unspecific signal seen with organ homogenates from 
wt mice, implying that the artificial GS promoter was activated in all tested organs. 
Among these, the heart revealed the highest activity of the measured organs, while 
gut and lung had the lowest. 
 
Figure 38: Amount of firefly luciferase in the homogenate of heart, liver, kidney, lung and gut from male GS mice 
versus wt mice. Luciferase activity was detected in the heart, liver, kidney, lung and gut of GS mice (black bars), 
implying GS promoter activation in all tested organs. n=3, mean ±SD are given. 
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Figure 40: Female GS mouse scanned with PET. The tracer 
18
F-FHBG rapidly diffused in the whole body, producing a 
strong signal in gut and heart after 60-120 min. MR imaging was used to determine the position of organs. 
Representative of n = 2. Pictures were taken by A. Schmid. 
 
4.4.2 Glutamine Synthetase Gene Expression “Atlas” in Murine Organs 
Since GS is a direct target of Wnt/ β-catenin signaling, the GS reporter mouse could be 
used to generate a glutamine synthetase gene expression “atlas”, which indirectly 
predicts in which organs and cells Wnt signaling is active. 
Knowing from preliminary testings that glutamine synthetase was found in liver, 
kidney, gut and heart, the first question was wherever else it is expressed. Therefore, a 
close collaboration with Prof. Bence Sipos and Dr. Ursula Kohlhofer, Department of 
Pathology and Neuropathology, General Pathology, University Hospital Tübingen, was 
carried out to isolate 30 organs from male and female GS mice to create a GS gene 
expression atlas (table 21, figure 49). Cryo slices of all organs were stained with X-Gal. 
Strikingly, most GS was expressed in the brain area-of-interest cerebellum, 
hippocampus and caudate/ putamen, more precisely confined to the nuclear and 
cytoplasmic areas. As already known from previous studies of our group (Braeuning et 
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al. 2006), GS was expressed in pericentral hepatocytes. The digestive tract displayed 
GS expression in the squamous epithelium of the esophagus, in parietal and chief cells 
in the stomach, in smooth muscle cells of the colon and less in basal cells of the tunica 
mucosa in the medial and distal colon while nearly no GS promoter activity was 
monitored in the mucosa of the salivary gland. No GS promoter activity was reported 
in the three parts of the small intestine, duodenum, jejunum and ileum, in pancreas, 
spleen and in the proximal colon. The gall bladder lacks in the slides. Organs which 
have to do with urine excretion were different in their GS expression. The kidney had a 
high GS level in cells of the outer medulla and the cortex. GS expression was detected 
in the adrenal gland in the zona fasciculate of the cortex, but the urinary bladder 
showed nearly no GS expression. Reproductive organs were examined, too. Leydig 
cells of the testis displayed a high amount of GS expression, while only less GS was in 
the granulosa cells in the ovary. Cardiomyoctes, smooth myocytes and myoctes in the 
skeletal muscles also displayed a strong GS expression, which was consistently located 
nuclear, while less GS was expressed in the nucleus of the bronchial epithelium in the 
lung. Additionally, GS promoter activity was found in adipocytes of the thymus and not 
in thymus parenchyma. Finally, the sternum displayed no GS promoter activity. The 
staining on this slide was attributable to the remaining skeletal muscle cells. No 
differences between male and female were observed in all organs. 
Figure 49 with LacZ stained organ slices is attached in the supplementary. 
Table 21: Localization of glutamine synthetase in mice, which indirectly predicts in which organs and cells Wnt 
signaling is active. GS expression was determined via LacZ staining of more than 30 organs from male and female 
GS reporter mice; N, nuclear; C, cytoplasmatic; 0, no GS promoter activity. 
# organ Male GS mouse Female GS mouse 
1 Cerebellum 
brain in general (N & C) 
 
2 Hippocampus 
3 Caudate/ putamen 
4 Salivary gland cells of the mucosa 
5 Thyroid gland 0 
6 Esophagus & trachea squamous epithelium 
7 Stomach parietal cells and chief cells 
8 Duodenum 0 
9 Jejunum 0 
10 Ileum 0 
11 Coecum smooth muscle cells (N) 
12 Colon proximal 0 
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13 Colon medial less in basal cells of the tunica mucosa 
14 Colon distal less in basal cells of the tunica mucosa 
15 Pancreas 0 
16 Liver pericentral hepatocytes (N & C) 
17 Gall bladder lacks in the slide 
18 Spleen 0 
19 Kidney outer medulla and cortex 
20 Adrenal gland zona fasciculata of the cortex 
21 Urinary bladder 0 
22 Ovary - less in granulosa cells 
23 Uterus - 0 
24 Cervix - 0 
25 Testis Leydig cells - 
26 Heart cardiomyocytes (N) 
27 Thymus 0, but in adjacent adipocytes 
28 Lung less in bronchial epithelium (N) 
29 Muscle skeletal myocytes (N) 
30 Sternum skeletal muscle cells, but nothing in bone marrow 
 
4.4.3 Monitoring Tumor Formation in GS Reporter Mice 
In the following experiment, formation of Ctnnb1 mutated liver tumors should be 
traced with non-invasive imaging technologies in GS reporter mice. In order to 
generate Ctnnb1 mutated liver tumors, mice were given a single intraperitoneal DEN 
dose of 90 µg/g body weight followed by chronic treatment with 0.05 % PB for 25 
weeks as previously described (Moennikes et al. 2000, also see 3.1.7). When complying 
the protocol, nearly 80 % of liver tumors harbor activating mutations in Ctnnb1 
(Aydinlik et al. 2001), while only few tumors are mutated in Ras or Raf. The special 
thing about the GS reporter mice used in this experiment is that they express 
thymidine kinase 1 under the control of the GS promoter, specifically activated in 
Ctnnb1 mutated preneoplastic lesions and tumor cells. The quantitative readout of 
Tk-1 activity was performed using 18F-FHBG as a probe in PET. Commencing 12 weeks 
after tumor initiation, the tumor bearing mice were measured by PET and MRI every 
2-4 weeks to pursue tumor development. First tumor lesions could be depicted in MR 
images starting approximately in week 18 of PB treatment. As illustrated in figure 41, 
liver tumors in week 22 and 25 of PB treatment could only be detected by MRI (white 
arrows). 
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Contrary to the expectations, however, we were unable to obtain specific signals in the 
PET analysis of tumor-bearing mice using 18F-FHBG and the Tk-1 reporter system after 
25 weeks of tumor promotion (figure 41 C). The tracer, however, was functional and 
accumulated in the intestinal tract and bone marrow. 
 
Figure 41: Representative PET and MRI images of one individual GS mouse after initiation with DEN and liver 
tumor promotion with PB for 25 weeks showing liver tumor growth. Tumors (white arrows) appeared as intensive 
lesions in the liver with MRI. PET was performed using 
18
F-FHBG as a tracer, but PET showed no tumors; they were 
only detectable by MRI. A, MRI after 22 weeks with PB treatment; B, MRI after 25 weeks with PB treatment; C, PET/ 
MRI fusion after 25 weeks with PB treatment. St, stomach; L, left; R, right; V, ventral; D, dorsal; I, inferior; S, 
superior. Pictures were taken by A. Schmid. 
 
Figure 42 shows the liver tumor progression over time measured via MRI. The data 
points represent the total liver tumor volume of one animal, 6 animals were measured 
at every indicated time point. Tumor growth was very heterogenous. Some mice began 
to develop liver tumors after 18 weeks of PB treatment, while other mice showed 
nearly no visable changes even after 22 weeks of PB treatment. At the 22-week time 
point, only MRI was performed instead of a PET/ MRI measurement. The MRI protocol 
varied slightly: thus, the detected tumor volumes at week 22 were higher in some 
animals, due to the sharper and brighter images, as visible in figure 41. After 25 weeks 
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of PB treatment, all 6 mice had liver tumors; an exact determination of the tumor 
volume with MRI was only possible, however, in 3 animals. 
 
Figure 42: Monitoring of liver tumor burden via MRI in GS mice. Liver tumors were initiated with DEN and 
promoted with PB for 25 weeks. The liver tumor volume of 6 animals is shown at different time points. Horizontal 
bars represent the mean tumor volumes. M1 - M6, mouse 1 - mouse 6. 
 
Because liver tumors couldn’t be detected with PET, the question is whether these 
tumors are Ctnnb1 mutated and show the well-known phenotype or not. Only tumors 
that are mutated in the Ctnnb1 gene can be visualized with PET using a tracer for Tk-1 
in this experiment. To substantiate the phenotype of developed liver tumors and to 
show activity of one other reporter gene, LacZ, two mice were sacrificed after 25 
weeks of PB exposure. The livers were cut out and analyzed. One untreated littermate 
was used as a control. Ctnnb1 mutated liver tumors could be visualized post mortem 
with X-Gal staining, using the second reporter gene, LacZ, which is under the control of 
the GS promoter, too. In the X-Gal staining, Ctnnb1 mutated tumors distanced 
theirselves from the surrounding tissue by a blue color. X-Gal positive tumors showed 
also the expected expression of the GS protein, but not all GS positive tumors 
displayed the same strong X-Gal staining (figure 43).  
 
Time of PB treatment [weeks] 
T
u
m
o
r 
vo
lu
m
e
 [
m
m
3
] 
17 18 19 20 21 22 23 24 25 26
0
10
20
30
40
50
 M1
 M2
 M3
 M4
 M5
 M6
 mean
Results Page 99 
 
Figure 43: X-Gal and GS staining of liver lobes in GS reporter mice after tumor initiation with DEN and promotion 
with PB or no treatment. Livers excised after 25 weeks of PB treatment (+) harbored GS positive tumors (positive 
for X-Gal and GS), while untreated control mice (-) displayed no hepatic changes. Tumors are indicated with black 
arrows. Pictures were taken with 2.5x and 10x magnification. 
 
Additionally, further immunohistochemical analyses of liver sections from tumor-
bearing mice were performed to determine the tumor phenotype. Glucose-6-
phosphatase (G6pase) was used as a general tumor marker to visualize liver tumors. 
GS positive liver tumors were mostly negative for G6pase relative to the surrounding 
normal tissue. X-Gal and GS positive tumors showed the expected expression of 
Cyp1a2 and Cyp2c. The mutation analyses of GS positive liver tumors also confirmed 
the 100 % concordance between GS expression and Ctnnb1 mutation. 6 out of 6 
examined GS positive tumors were mutated in either codon 33 (4 tumors, 67 %) or in 
codon 32 (2 tumors, 33 %) of the Ctnnb1 gene. The other GS positive tumors were too 
small to gain enough tumor DNA for mutation analysis. 
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Figure 44: Phenotype of immunostained liver tumors from GS mice. 
β-catenin signaling were positive for Cyp1a2
tumor marker. GS positive tumors showed
 
To sum up, GS positive and Ctnnb1
PET using the Tk-1 reporter system
the GS promoter and expressed in 
via MRI turned out to be a reliable tool to detect and monitor growth characteristics of 
liver tumors, even at an early stage
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5. Discussion 
The present thesis comprises work on two different projects. 
Project A dealt with the potential of long non-coding RNA Gtl2 as a biomarker for NGC 
and tumor suppressor and its characterization. For this purpose, tissue material from 
animals treated with different NGC and GC compounds was examined. Access to 
murine, rat and human tissue, normal liver and tumor tissue was available. As cell 
culture experiments were not satisfactory, switching to animal models was the logical 
consequence. Due to the lack of an appropriate knockout mouse model, Gtl2 was 
constitutively overexpressed in murine liver by the use of adenoviral Gtl2. 
Project B, in cooperation with the group of Prof. Bernd Pichler, was intended to life 
image the development of liver tumors in an engineered glutamine synthetase 
reporter mouse by PET and MRI. For tumor generation, animals were treated with DEN 
as an initiator followed by chronic PB treatment to promote the development of 
Ctnnb1 mutated tumors. Mice were then scanned for tumor development at the 
Laboratory of Preclinical Imaging and Imaging Technology in Tübingen on a monthly 
basis. Additionally, this reporter mouse was used to generate a glutamine synthetase 
gene expression “atlas”, which indirectly predicts in which organs/ cells Wnt signaling 
is active. 
 
5.1 The Role of the Imprinted Dlk1-Dio3 Cluster in Liver 
Emerging evidence suggests that non-coding RNAs play an important physiological role 
in a variety of biological processes, while aberrant expression can promote cancer 
(Cheetham et al. 2013). Micro RNAs have well ascertained expression patterns by 
silencing specific target genes. Much less is known about long non-coding RNAs 
(lncRNAs); their function in cancer remains to be elucidated. 
Lempiainen et al. 2013 performed a miRNome analysis with liver samples from mice 
treated with PB, the classic non-genotoxic rodent carcinogen (Whysner et al. 1996), to 
search for an early biomarker for NGC. Noticeable, most PB-induced miRNAs were 
transcribed from the Dlk1-Dio3 imprinted cluster on chromosome 12. This cluster 
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encodes for a number of protein coding genes as well as ncRNAs, including long non-
coding RNA Gtl2. A connection between Gtl2 and carcinogenesis has been observed in 
many different tissues and species (Benetatos et al. 2011), identifying Gtl2 as a tumor 
suppressor (Zhou et al. 2012), but the findings are to some extent inconsistent. To 
date, presentation of a mechanism for long non-coding RNA Gtl2 action has failed 
although Gtl2 is currently the most studied transcript of this region. The aim of this 
thesis was to identify targets and molecular functions of Gtl2 in hepatocarcinogenesis 
and to verify its role as a biomarker for NGC and as a tumor suppressor. 
Recent studies performed by Novartis in cooperation with our laboratory indicated a 
dependence of Gtl2 expression on β-catenin and CAR and therefore supported a role in 
PB-dependent tumor promotion (Lempiainen et al. 2013). This was corroborated by 
the finding of an augmented Gtl2 expression in Ctnnb1 mutated mouse liver tumors, 
but not in their Ras and Raf mutated counterparts, when determined via qPCR. The 
link between β-Catenin and Gtl2/ MEG3 expression was further strengthened by the 
observation of an increase in MEG3 expression in CTNNB1 (encoding human β-Catenin) 
mutated human hepatoblastoma, a rare liver neoplasm occurring in small infants and 
children (Darbari et al. 2003). Recent analysis demonstrated an 80 % prevalence of 
mutations in CTNNB1 (Schmidt et al. 2011) in this tumors. Since the tumor cells in the 
human cancers were never exposed to PB, this evidence suggests that overexpression 
of Gtl2/ MEG3 in the respective Ctnnb1/ CTNNB1 mutated mouse and human liver 
tumors is a consequence of constitutive activation of the Wnt/ β-Catenin signaling 
pathway and not simply caused by PB, even though PB can induce a similar response in 
normal mouse liver. 
Expression of Gtl2 was lower in Ras/ Raf mutated liver tumors when compared to 
normal liver. Gtl2 is physiologically expressed in a single layer of hepatocytes 
surrounding the central veins (see Figure 30 B). Exactly the same hepatocytes do 
physiologically express the enzyme glutamine synthetase (GS), a marker for the 
activated Wnt/ β-catenin pathway in these hepatocytes. GS expression is completely 
shut down when oncogenic Ras signaling is activated in these cells (Braeuning et al. 
2007). Therefore the reduction in Gtl2 expression in the Ras mutated liver tumors is a 
consequence of activation of the Ras/ MAP kinase pathway. 
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PB treatment was not able to rescue the physiological expression pattern, since it did 
not lead to a reexpression of Gtl2 in Ras and Raf mutated liver tumors. The most likely 
explanation for this lack of effect of PB is that activation of MAP kinase signaling may 
override the PB response which is linked to CAR and β-catenin signaling as 
demonstrated in the paper of Lempiainen et al. 2013. In fact there is evidence for a 
reciprocal inhibitory crosstalk between the MAP kinase and the Wnt/ β-catenin 
pathways regulating zonation in liver (Hailfinger et al. 2006, Braeuning et al. 2006, 
Braeuning et al. 2007, Zeller et al. 2013), which would also explain the concomitant 
downregulation of GS and other markers in these tumors. Interestingly, however, was 
PB not without effect in the Ras/ Raf mutated tumors, but it led to a significant 
reduction of Gtl2 expression in the tumor cells. This inhibitory effect of PB is probably 
not mediated through CAR, since the nuclear receptor is downregulated in the Ras/ 
Raf mutated liver tumors (Stahl et al. 2005, Strathmann et al. 2006). It is of note, that 
PB does not promote the outgrowth of Ras mutated mouse liver tumors but rather 
inhibit their growth (Lee et al. 1998, Lee 2000, Moennikes et al. 2000) and there may 
be a possible, but unknown mechanistic link between the two phenomena. PB inhibits 
Wnt/ β-catenin signaling and cell proliferation in various mouse hepatoma cell lines, 
when incubated at a concentration between 1 and 3 mM (Braeuning, unpublished). 
These cells are devoid of CAR expression and do not express Gtl2 (own observation). 
The PB liver concentration at a diet concentration of 0.05 %, frequently used in tumor 
promotion experiments, is ~12 µg/g liver (Braeuning et al. 2014). This is also the diet 
concentration at which inhibition of Ras mutated tumors was observed (Moennikes et 
al. 2000). Roughly estimated, 12 µg/g equal 0.05 mM of PB in liver, suggesting that the 
Ras mutated hepatocytes in vivo are more responsive to the inhibitory effects of the 
barbiturate. Not only Gtl2 was decreased in expression in PB treated Ras/ Raf mutated 
tumors, but the whole Dlk1-Dio3 cluster seemed to be affected: maternally imprinted 
genes Rian and Mirg showed slight downregulation, and the paternal protein coding 
genes Rtl1 and Dio3 were strongly reduced in their expression. Probably a single 
enhancer regulates several genes in the cluster, or one gene within the cluster acts in 
cis to transcriptionally silence other genes (Royo and Cavaille 2008). Kota et al. 
identified maternal non-coding RNAs expressed from the intergenic differentially 
methylated region (IG-DMR) that control Dlk1-Dio3 domain regulation (Kota et al. 
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2014). Apparently, PB, through an unknown but probably CAR unregulated 
mechanism, modulates the activity of this “master gene” in the Ras/ Raf mutated liver 
tumor cells. 
CAR agonists are a group of structurally diverse chemicals that all induce Cyp2b 
enzymes (Ueda et al. 2002), which can therefore serve as a biomarker for CAR 
activation. It was demonstrated that beside PB, other CAR agonists like PCB 153 were 
capable of altering the expression of Dlk1-Dio3 cluster genes, especially Gtl2, 
reaffirming the CAR dependence of Gtl2 expression. PCB 153 behaves like PB and 
selects for Ctnnb1 mutated hepatocytes when administered to mice as a tumor 
promoter (Strathmann et al. 2006). The other PCB examined was the planar dioxin-like 
PCB 126 activating the aryl hydrocarbon receptor (AhR). In this case, Cyp1a1 can be 
used as a biomarker (Bock and Kohle 2009). PCB 126 was also active in changing the 
expression of Dlk1-Dio3 cluster genes, especially Gtl2, similar albeit less pronounced 
when compared to PCB 153. This may suggest that AhR activation may also lead to 
increased expression of Gtl2. There is some evidence, however, for a crosstalk 
between AhR and CAR signaling (Petrick and Klaassen 2007), in that that the activated 
AhR transcriptionally regulates CAR. 
Two other CAR agonists examined in this study were the fungicides cyproconazole and 
prochloraz. Many conazoles are known to induce or inhibit hepatic cytochrome P450 
isoforms. In mice, Cyp2b and Cyp3a4 have been reported to be induced in the liver, 
mediated by CAR and PXR nuclear receptors (Maglich et al. 2002, Peffer et al. 2007, 
Hester et al. 2012). Thus, it was not surprising that Dlk1-Dio3 cluster genes and 
Cyp2b10 revealed increased expression in conazole treated mice. Prochloraz is known 
to activate the AhR biomarker Cyp1a1 in rat liver (Vinggaard et al. 2005, Vinggaard et 
al. 2006). In the present study with mice, Cyp1a1 and Cyp2b10 expression were both 
elevated, suggesting an additional effect of prochloraz on CAR activity, which would 
explain its effect on Gtl2, Rian, Mirg, Rtl1 and Dio3 expression. 
PB is a well-documented non-genotoxic hepatocarcinogen in rodents (Lee 2000, 
Whysner et al. 1996), but the relevance of this effect for humans is debated. So called 
“humanized” mouse models provide a powerful approach for understanding possible 
species differences. Recently, an initiation-promotion study conducted in our 
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laboratory with “humanized” CAR/ PXR (hCAR/ hPXR) mice demonstrated that these 
mice respond to PB treatment with Cyp2b10 induction, like the wildtype mice, and 
developed liver tumors albeit less than the wildtype mice (Braeuning et al. 2014). 
Luisier et al. 2014 demonstrated an augmented Gtl2 level in livers of hCAR/ hPXR mice. 
These results indicate that the human receptors, when expressed in the mouse 
genomic environment, respond similarly to PB like the mouse receptors. This 
toxicologically important statement is underlined by the observation that Gtl2 and 
other Dlk1-Dio3 cluster genes were also increased in expression in conazole treated 
hCAR/ hPXR mice, but to a lesser extent, when compared to the respective wildtype 
controls. Species differences in CAR activation by direct ligands are well-documented 
and are due to a structural diversity in the ligand binding sites (Nims et al. 1993, 
Auerbach et al. 2005). CITCO, for example, is selective for human CAR while TCPOBOP 
is selective for mouse CAR (Auerbach et al. 2005, Nims et al. 1993). PB, by contrast, is 
an indirect CAR activator not directly binding the receptor, and is active in both human 
and rodent hepatocytes (Kawamoto et al. 1999, Yang and Wang 2014). The molecular 
mechanism by which conazoles activate CAR signaling is not completely understood, 
but maybe through a signal transmission cascade via the glucocorticoid receptor 
(Pascussi et al. 2003, Duret et al. 2006). Given that Gtl2 is a biomarker for PB-type 
NGC, the results of this study demonstrate that conazoles are also active on the human 
receptors expressed in the mouse background. 
Among the most widespread non-genotoxic carcinogens are peroxisome proliferators 
(Stanley et al. 2006) with clofibrate (CF) as a prominent example. Peroxisomes are 
small organelles involved in β-oxidation and in the biosynthesis of bile acids and 
cholesterol (Mannaerts and Van Veldhoven 1993). Chronic administration of 
peroxisome proliferators to rats and mice results in the formation of hepatocellular 
carcinoma (Reddy et al. 1979). The mechanism of tumor formation is not completely 
understood, but maybe through oxidative stress resulting in DNA damage or enhanced 
cell proliferation and decreased apoptosis, respectively (Benigni et al. 2013). Chronic 
administration of CF to rats results in the development of preneoplastic lesions in the 
liver with an altered gene expression profile, as described by Ittrich et al. 2003. The 
biomarkers for CF and PB, Cyp4a and Cyp2b, respectively, were significantly 
upregulated in liver, demonstrating that the two NGC, given for 10 weeks, were active 
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as expected. However, the only very moderate and not statistically significant 
upregulation of Gtl2 ín the treated animals suggests that Gtl2 has limited potential as 
general NGC biomarker in other species than the mouse. However, it is not clear, 
whether peroxisome proliferators are able to upregulate Gtl2 in mouse liver. This is 
presently under investigation in the MARCAR project. 
As β-catenin is important for Gtl2 expression in mice, it was investigated to what 
extent a treatment that leads to the induction of Gtl2 correlates with an effect on the 
β-catenin signaling pathway. Cyp7a1 was chosen as a suitable readout, since it was 
described to be transcriptionally upregulated in Ctnnb1 mutated but downregulated in 
Ha-ras mutated mouse liver tumors (Unterberger et al. 2014). As expected, Cyp7a1, 
which catalyzes the rate limiting step of bile acid synthesis from cholesterol, was 
increased upon PB and CF treatment in rat liver, suggesting an activation of β-catenin 
signaling by the two NGCs. However, two other biomarkers, Sds and Gls2, were 
upregulated in the rat liver study, while their expression is clearly attenuated by active 
β-catenin in mouse liver (Unterberger et al. 2014). A change in β-catenin signaling may 
therefore not be the cause for the almost complete lack of response in Gtl2 expression 
in CF and PB exposed rats. In the rat liver bioassay reported by (Ittrich et al. 2003) not 
only NGCs but also two well-known genotoxic carcinogens, namely 
N-nitrosomorpholine (NNM) and 2-acetlyaminofluorene (AAF) were investigated. Liver 
samples from the treated mice were still available for analysis. The results with respect 
to Gtl2 expression were not conclusive. NNM did not produce significant effects. AAF, 
however, clearly enhanced Gtl2 expression in males but reduced its expression in 
females. This gender differences in response are interesting, since they correlate with 
another gender difference in response: male rats respond more sensitive to AAF 
(Ittrich et al. 2003). From an overarching perspective, the results obtained with NGC 
and GC in mice and rats with respect to their effects on Gtl2 expression in the liver are 
disappointing. Gtl2 may serve as a NGC biomarker in mouse liver but not in the rat and 
it does not seem to discriminate between NGC and GC when taken the rat data. Data 
from GC-exposed mice are presently generated within the MARCAR project. The 
relevance of these results for humans needs to be further investigated. 
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One of the aims of modern toxicology is to reduce, refine and replace experimental 
animal use. Moreover, mechanistic investigations are often easier to perform using in 
vitro systems. For this reason, further experiments on Gtl2 were carried out with 
cultures of freshly isolated hepatocytes of mice. Primary hepatocytes are frequently 
used in vitro models for investigating drug metabolism and signaling pathways. 
(Klingmuller et al. 2006). Cyp2b10 expression, as an indicator for CAR activation, was 
upregulated after 24 h of treatment of primary mouse hepatocytes but returned to 
nearly basal level at a later time point of investigation. This was likely due to the well-
known difficulty in maintaining a differentiated phenotype over culture time (Guguen-
Guillouzo and Guillouzo 2010). Gtl2 mRNA levels were unchanged in the PB exposed 
primary hepatocytes culture. This could be due to the fact that cells in culture do not 
respond as in liver. On the other hand, PB-mediated upregulation of Dlk1-Dio3 genes 
in mouse liver requires weeks of exposure and is not significant before treatment day 7 
in vivo (Lempiainen et al. 2013). Primary hepatocytes have a limited life span, making it 
very difficult to ensure experiments over a period of several weeks. Thus, primary 
hepatocytes do not serve as an adequate system for investigating Gtl2 targets and Gtl2 
regulation. 
Loss of Gtl2 expression has been found in all cancer cell lines derived from bladder, 
colon, breast, lung and liver described in literature (Braconi et al. 2011, Benetatos et 
al. 2011, Zhou et al. 2012) and examined in this thesis, except one. Surprisingly, a 
recently published pediatric human hepatocellular line, named HC-AFW1, derived from 
a liver neoplasm of a 4 year old boy through culturing of primary tumor specimens 
showed clear MEG3 expression accompanied by strong β-Catenin expression. This cell 
line revealed a deletion of 49 bp in exon 3 of CTNNB1 (Armeanu-Ebinger et al. 2012). 
HC-AFW1 is the first pediatric HCC cell line not generated on the background of viral 
hepatitis or liver cirrhosis like other cell lines (Eicher et al. 2011), thus excluding virus- 
or ethanol-induced side effects. In literature, it was suggested that the ability of Gtl2 to 
block proliferation might be a reason why Gtl2 expressing cell lines could not be 
established (Zhang et al. 2003, Mitra et al. 2012). However, another explanation seems 
more convincing: HC-AFW1 cells were special as they express the CAR receptor, which 
is lacking in all other cell lines investigated and is necessary for Dlk1-Dio3 gene cluster 
expression (Lempiainen et al. 2013). The CAR dependence was underpinned by the 
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identification of an upstream region of one of the three Gtl2 transcript variants which 
could be determined as directly regulated by CAR expression, given that this reporter 
vector was the only one with a remarkable and significant inducible luciferase signal in 
response to CAR. 
As it had not been possible to manipulate MEG3 expression in HC-AFW1 via siRNA, 
another way to alter gene expression has been tested. Gtl2 is an imprinted gene 
expressed from the maternal allele, which means that the maternal allele is 
unmethylated while Gtl2 is transcribed. Methylation within the promoter region has 
been associated with loss of MEG3 expression in human pituitary tumors (Zhao et al. 
2005). Demethylating the promoter might switch on gene expression. By using the 
methylation inhibitor 5-azadeoxycytidine (5-Aza-dC), Gtl2 mRNA levels could be raised 
in hepatoma cells of line 53.2b to a detectable, but still very low level. Reexpression of 
the unmethylated form during exposure to 5-Aza-dC occurs also in the human HCC cell 
lines HepG2 and Huh7 (Zhao et al. 2005). Because methylation inhibitors have no 
pathway specificity and the achievable Gtl2 level was very low, another cell system 
with engineered Gtl2 expressing cells was established. The respective line was termed 
70.4 UT K54. Clontech’s Tet-On Advanced Inducible Gene Expression System was used, 
which is a tightly regulated system that produces upon request expression of a gene of 
interest in target cells, in this case Gtl2, through adding the inducer doxycycline. 
Additional advantages of the system are its extremely low basal activity and the 
induction with a prokaryotic antibiotic, not having a known effect on eukaryotes when 
used at the concentrations required by Clontech (Clontech 2012). Ahler et al., 
however, criticize potential off-target effects through doxycycline (Ahler et al. 2013). 
For further experiments, the intracellular localization of Gtl2 in 70.4 UT K54 cells based 
on digitonin cell fractionation was examined. The results demonstrated that the 
majority of the transcript was located in the nucleus, hence in analogy to the 
physiological situation in mouse hepatocytes in vivo. Cytoplasmic expression of MEG3 
in non-neoplastic liver has also been described (Braconi et al. 2011), but in general, 
Gtl2 localization was reported to be nuclear or in both compartments (Schuster-
Gossler et al. 1998, Kota et al. 2014). In the nucleus, it has been found associated with 
chromatin (Mondal et al. 2010). The physiological localization of Gtl2 in 70.4 UT K54 
cells primed this cell line to perform Gtl2 target search. 
Discussion Page 109 
RNA expression patterns in 70.4 UT K54 cells pointed out that forced Gtl2 expression 
resulted in a significant number of differentially regulated ncRNAs, while protein 
coding genes were underrepresented in this search. Among the latter were numerous 
olfactory receptors (Olfr), G protein coupled receptors mainly expressed in olfactory 
sensory neurons in the olfactory epithelium. All but one were found to be 
downregulated in the Affymetrix global gene expression analysis after forced Gtl2 
expression in 70.4 UT K54 cells. Olfr expression in a liver-derived cell line is at first 
glance unexpected and may be a microarray artifact, since microarray experiments are 
widely recognized as being noisy (Bammler et al. 2005). However, there is growing 
evidence that Olfr may be expressed and have additional physiological functions in 
other tissues (Feldmesser et al. 2006), and some Olfr are even overexpressed in tumor 
cells (Sanz et al. 2014). The mouse genome contains approximately 1,200 Olfr genes 
(Fuss et al. 2007). Given this large number, a false-positive response of one or a few 
Olfr genes is not unlikely. However, the fact that 10 out of 108 protein coding genes 
were Olfrs, in other words that this group of RNAs was largely overrepresented speaks 
agaist the idea of an artefact, even though the changes in the individual Olfr genes 
could not be validated via qPCR. Strikingly, most of the 10 deregulated Olfrs in 70.4 UT 
K54 cells were clustered on mainly two chromosomes. Another group of 
overrepresented genes in the microarray experiment consisted of genes of the 
immune system. 12 out of 108 protein coding genes belong to this “cluster” and were 
deregulated. A mechanistic link between the immune and olfactory systems is seen in 
their monoallelic expression. Monoallelic expression means that only one allele of a 
gene is actively transcribed, while the other is silent. The expression of a single 
olfactory or immune system gene is determined by an enhancer element on another 
chromosome. The enhancer associates with one of many promoters on different 
chromosomes by folding of the DNA (Keverne 2009). Since polycomb group proteins 
are linked to monoallelic gene silencing (Alexander et al. 2007, Zhang et al. 2014), it is 
possible that Gtl2 acts via the enhancer polycomb repressive complex 2 to regulate the 
expression of olfactory and immune system genes (figure 46). 
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Figure 45: Schematic representation of the interplay between Gtl2, PRC2 and Olfr to express Olfr. The expression 
of a single olfactory (or immune system) gene is determined by the enhancer PRC2 on another chromosome, which 
is directed to the Olfr by Gtl2 (adapted from Keverne 2009). 
Through Gtl2-protein binding studies, no targets could be identified, except for some 
“unspecific” binding partners such as ribonuclear and heatshock proteins. Random 
integration of Gtl2 in the genome may explain this behavior, given that the gene 
location plays a pivotal role for its function (Ulitsky et al. 2011). Presumably, Gtl2 might 
need components not expressed in cell culture which are required for its physiological 
action, like CAR, or polycomb repressive complex 2 (PRC2), or other yet unknown 
molecules. PRC2, for example, is a key epigenetic regulator responsible for histone 
methylation (Margueron et al. 2009). Because none of the PRC2 complex components 
exhibit a DNA binding domain, Rinn and Chang assume targeting of the complex by 
chromatin associated long non-coding RNAs (Rinn and Chang 2012). Gtl2 is believed to 
be one of these RNAs as JARID2 and EZH2, both part of the PRC2 complex, directly bind 
Gtl2 in vivo (Kaneko et al. 2014). Although expressed in HeLa cells (Beckedorff et al. 
2013), it is dubious whether PRC2 complex proteins are transcribed in the murine liver 
cell lines examined. The results obtained with the cell culture systems were obviously 
not sufficient for identifying consequences resulting from Gtl2 overexpression in the 
liver. Mice offer a more realistic system to study physiologic liver functions. Two Gtl2 
knockout (KO) mouse models have been reported in literature. Takahashi et al. created 
a Gtl2KO mouse harboring a 10 kb deletion in exons 1 to 5. Mice carrying a maternal 
deletion have a milder phenotype and are able to survive 4 weeks, whereas mice with 
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a paternal deletion suffer perinatal lethality, indicating that Gtl2 plays an important 
role in embryonic development. Due to their short lifetime, these animals are 
unsuitable for tumor promotion experiments. Only homozygous mutants survive 
(Takahashi et al. 2009). Another mouse model exists with locus specific defects in 
miRNA expression (Cavaillé, unpublished), but was not made available for our 
investigations. Hence, a mouse system with altered Gtl2 expression in their 
hepatocytes was created to study Gtl2 dependent effects in vivo. To this end, an 
adenoviral Gtl2 expressing construct was used. After testing the functionality of the 
construct in vitro, showing a multiplicity of infection (MOI) dependent Gtl2 expression, 
it was injected into C3H mice via tail vein, while a GFP construct served as a control. 
Two different time points were chosen, since it was not clear how long Gtl2 needs to 
transiently integrate and how long expression will take place. As a rough guide to 
determine end points, verbal information of our project partner was used, who had 
designed the viral construct. Four and eight days of viral incubation were considered to 
be sufficient. Taken from the results of the determination of the RNA expression level 
and from the Gtl2 ISH results, the 4 day time point was the one with a remarkable Gtl2 
expression and considered to be relevant for further investigations. Gtl2 was 
expressed not only around the central vein as it is physiological, but spotted over the 
whole liver. After 8 days, the return to the normal level was nearly completely 
performed, implementing a depletion of the viral construct and/ or its RNA. 
Since Wnt/ β-catenin and CAR signaling control the perivenous phenotype and 
therefore also induce a “perivenous" phenotype in Ctnnb1 mutated tumors in which 
both pathways are activated, the initial assumption was that Gtl2 is involved in the 
regulation of perivenous gene expression. Snyder et al. identified a transcription factor 
that modulates β-catenin signaling via direct regulation of the Gtl2 promoter (Snyder 
et al. 2013), suggesting a connection not only between β-catenin signaling and Gtl2 
expression but also vice versa. Phenotypic changes, however, didn’t occur after 
adenoviral Gtl2 transduction in vivo. Pericentral markers remained restricted to their 
original location. Classic liver zonation with perivenous expression of GS accompanied 
by Cyp1a2 expression, as previously described by Hailfinger et al. 2006 and Braeuning 
et al. 2007, was seen in all groups. Also the initial assumption that Gtl2 may lead to a 
PB mimetic gene expression could not be confirmed by immunohistochemistry since 
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the classic PB target Cyp2b was not altered after adenoviral Gtl2 transfer. Conspicuous 
was an augmentation of inflammatory cells after 8 days of treatment, both in the Gtl2 
and GFP group. The viral particles used were deleted in E1 and E3 genes, which render 
it replication deficient (AgilentTechnologies 2013). But it is known that E1 deficient 
adenoviral vectors express viral antigens that activate cytotoxic lymphocytes in the 
liver of mice and destroy transgene expressing hepatocytes (Yang et al. 1994), leading 
to an immune response in the liver which could explain the time-dependent vanishing 
Gtl2 expression observed. Probably, apoptotic cells should also be increased along 
with the immune response, since it is known that cytotoxic T-cells eliminate virus 
infected cells by the induction of apoptosis (Janeway et al. 2001). Such an increase was 
seen after 8 days of treatment, both in the Gtl2 and GFP group. Although Gtl2 exerts a 
cis repressive effect on the adjacent protein coding gene Dlk1 by recruiting PRC2 
protein complex (Zhao et al. 2010), Dlk1-Dio3 cluster genes remained unaffected after 
adenoviral Gtl2 transduction. Kaneko et al. reported a depletion of EZH2, which is part 
of the PRC2 complex, upon ectopic expression of lncRNA MEG3. Further more, they 
speculated that an excess of MEG3, upregulated through lentiviral transduction, 
mediates this dominant negative effect (Kaneko et al. 2014). Such a depletion of the 
PRC2 complex expression in the present adenoviral system might be a reason for not 
detecting altered expression of PRC2 regulated genes after adenoviral transduction of 
Gtl2 in vivo.In contrast to normal cells, which only divide a restricted number of times 
before entering into growth arrest, cancer cells can be kept unfinitely in culture. The 
loss of negative cell cycle control can promote tumorigenesis. Given that Gtl2 is a 
potential tumor marker, it might directly or indirectly affect cell proliferation. Two key 
classes of regulatory proteins, cyclins (Ccn) and cyclin dependent kinases (Cdk) 
determine the cell cycle (Nigg 1995) which were measured on mRNA level. All 
examined cell proliferation associated genes, namely Ccnd1, Cdk2, Cdk4 and Pcna 
(proliferating cell nuclear antigen) were downregulated in the presence of Gtl2, 
suggesting retarded cell cycle progression in vivo. In line with these findings are data 
by Ying et al., who showed that downregulation of MEG3 increases cell proliferation of 
bladder cancer cells (Ying et al. 2013). In human glioma and gastric cancer, ectopic 
MEG3 expression inhibits cell proliferation by upregulating p53 activity (Wang et al. 
2012, Sun et al. 2014). P53 is also believed to inhibit Cdk2, Cdk4 and cyclin D1 activity 
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through p21 and p27 (Gartel and Tyner 2002). Colony formation was also repressed by 
MEG3 in a hepatocellular cancer cell line (Braconi et al. 2011). Taken together, these 
observations pointed towards an important role of Gtl2 in cell cycle regulation. 
Inhibition of cell cycle progression by Gtl2 points towards a role of the RNA as a tumor 
suppressor (Zhou et al. 2012). This view was supported by Gordon et al. who 
demonstrated that Gtl2 has a role in the control of tumor vascularisation by inhibiting 
angiogenesis (Gordon et al. 2010). On the other hand, as shown in this and a previous 
study by Lempiainen et al. 2013, expression of Gtl2 is upregulated by PB and other 
tumor promoters and increased in expression in Ctnnb1 mutated mouse and human 
liver tumors, suggesting an oncogene-like role of the non-coding RNA. Along these 
lines, a transcript functioning as a long non-coding RNA, potentially being Gtl2, able to 
promote HCC, was identified (Lau et al. 2014). Gtl2KO animals die early, too early to 
explore if lack of Gtl2 leads to tumor formation or inhibition. An initiation promotion 
study in a mouse constitutively overexpressing Gtl2 would help to answer this 
question. 
 
5.2 The GS Reporter Mouse as a Model to Determine GS Expression 
The second part of this work was the activity on a specific reporter mouse, harboring 3 
different reporters, namely FLuc (firefly luciferase), LacZ (β-galactosidase) and Tk-1 
(thymidine kinase 1) under the control of the glutamine synthetase (GS) promoter. As 
GS is a commonly known target for β-catenin signaling, (Cadoret et al. 2002) its 
promoter is specifically activated in β-catenin active tissue and Ctnnb1 mutated 
tumors. Thus, the GS reporter mouse could be used to generate a glutamine 
synthetase gene expression “atlas”, which indirectly predicts in which organs and cells 
Wnt signaling is active. The mouse had been generated commercially within the 
MARCAR project using a polycistronic 2A sequence from the foot and mouth disease 
that permitted the production of more than one protein from a single open reading 
frame (Funston et al. 2008). The multi reporter model was composed of GS-2A-LacZ-
2A-Tk-1-2A-FLuc, including a nuclear localization signal next to the LacZ open reading 
frame. 
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All preliminary testings concerning FLuc, LacZ and Tk-1 reporter gene activities were 
successful and advised this mouse for further studies. Due to the simple visualization 
and the simple protocol, LacZ reporter mice are a widespread model to detect spatial 
patterns of gene expression in vivo (Schmidt et al. 1998). In principle, cells that 
function to remove glutamate and ammonia seem to contain high levels of glutamine 
synthetase, whereas cells that synthesize glutamate contain much lower levels (Lie-
Venema et al. 1998). In the GS reporter mouse, most GS promoter activity was 
detected via X-Gal staining of tissue slices in pericentral hepatocytes and in the brain 
compartments cerebellum, caudate/ putamen and hippocampus, as already noticed by 
Venkatesh et al. 2013 and Liaw et al. 1995. They observed that GS is predominantly 
active in astrocytes of the brain, in kidney and in liver. By taking up ammonia and 
glutamate to synthesize glutamine, neurons are protected against toxicity (Suarez et 
al. 2002). Blutstein et al. showed the upregulation of glutamine synthetase in the 
hypothalamus and hippocampus both on mRNA and protein level (Blutstein et al. 
2006), which suggested an important role for cells in the central nervous system to 
modulate glutaminergic neurotransmission. Most GS promoter activity detected in the 
digestive tract was located in the stomach, confined to the parietal and chief cells, 
while some GS was expressed in the squamous epithelium of the esophagus and 
trachea, in smooth muscle cells of the coecum and less in the basal cells of the tunica 
mucosa in the medial and distal colon. Parietal cells remove ammonia which is 
released by bacteria, leading to its detoxification; high glutamine production, on the 
other hand, may lead to cell swelling (Nakamura and Hagen 2002). The other parts of 
the digestive tract containing pancreas, spleen, small intestine and the proximal colon 
showed no remarkable glutamine synthetase activity. James et al. determined GS 
expression in the whole human and rat gastrointestinal tract from esophagus to 
rectum with almost 90 % of the gastrointestinal tract GS activity in the lower stomach 
and only little in the colon, as also observed in this thesis. Organs involved in urinary 
excretion showed different GS expression patterns. The observation from literature 
that GS is widely expressed throughout the entire proximal tubule, the cortex and the 
outer medulla in the kidney of mice (van Straaten et al. 2006, Verlander et al. 2013) 
was in accordance to our findings. Renal GS, as an important regulatory component of 
the availability of ammonium comprises an important step through which acid-base 
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homeostasis is maintained (Conjard et al. 2003, Verlander et al. 2013). The adrenal 
gland contained little GS promoter activity in the zona fasciculate of the cortex, while 
the urinary bladder lacked GS promoter activity. It was high in Leydig cells of the testis 
as shown in literature (van Straaten et al. 2006) and also present in granulosa cells of 
the ovary. In literature, however, GS was undetected in ovary (van Straaten et al. 
2006). Xia et al. 2003 identified glutamine as a nutrient regulator of gene expression in 
the heart, which explains why the detected amount of GS in the heart of GS reporter 
mice was so high. Anatomically located in front of the heart is the thymus. There, GS 
promoter activity was predominantly seen in adipocytes and not in thymus 
parenchyma. GS expression in fat was already mentioned to be strongly upregulated 
during adipocyte differentiation (Bhandari et al. 1986). The lung, situated directly 
beside the thymus, showed less GS expression in the bronchial epithelium, as already 
seen in preliminary testings and mentioned in literature (van Straaten et al. 2006). GS 
promoter activity was observed in skeletal muscles in the GS reporter mouse. It is 
known that GS synthesizes glutamine in the muscle (Smith et al. 1984). Skeletal muscle 
constitutes for nearly ¾ of the endogenous glutamine synthesis in humans (Biolo et al. 
1995, Nurjhan et al. 1995). During fasting, muscle GS becomes an important glutamine 
producer for protein synthesis (He et al. 2010). In this thesis, GS expression was not 
observed in the sternum. The sternum is rarely examined concerning its glutamine 
synthetase expression. Olkku and Mahonen, however, observed GS activity in human 
osteoblastic cells controlling glutamate concentration in the bone environment (Olkku 
and Mahonen 2008). A larger study on GS expression was carried out by van Straaten 
et al.. They determined GS expression in 18 organs in the mouse (van Straaten et al. 
2006), as stated in the corresponding sections above. In contrast to our reporter based 
model with X-Gal staining to detect GS expression, they gained results with 
immunohistochemical staining for the GS protein. Clear advantages of LacZ reporter 
models against classic antibody staining are the high sensitivity, simple colorimetric 
detection and fast production of the reporter signal representing the promoter activity 
in contrast to the normal GS protein. Van Straaten et al. observed GS expression in the 
cytoplasm, while in our reporter mouse model, LacZ staining, which displayed GS 
promoter activity, was predominantely seen in the nucleus. The reason for this is that 
the LacZ reporter gene in the GS mouse encodes a nuclear localization signal. A similar 
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mouse model as presented here with the LacZ gene under the control of the GS 
promoter was already mentioned in literature, but extensive β-catenin signaling was 
generated with the injection of a β-catenin containing adenovirus. β-Galactosidase 
staining, representing GS activity, was restricted to the perivenous region in the liver, 
as observed in the present work, but no other organs were examined concerning their 
GS expression (Cadoret et al. 2002). 
In summary, the glutamine synthetase reporter mouse is a model ideally suited to 
examine GS activity, which indirectly predicts in which organs/ cells Wnt signaling is 
active in the whole mouse body. It can be said that organs with a high amount of GS 
promoter activity and therefore active Wnt signaling in different cell types of the brain, 
liver, testis, stomach and kidney function to remove glutamate and ammonia for 
detoxification and to produce glutamine as an energy source. Organs that produce 
glutamate harbor lower GS levels, (James et al. 1998, James et al. 1998), meaning less 
Wnt signaling. Examples for organs with a low GS expression are the small intestine 
and pancreas, as already reported by van Straaten et al. 2006. 
An enzyme based reporter system for PET uses herpes simplex virus thymidine kinase 
1 (HSV Tk-1), a reporter gene present in the GS mouse. This viral enzyme 
phosphorylates its natural substrate thymidine (Hughes et al. 1973) but also a broad 
spectrum of substrates, including acylguanosines. These compounds remain in the cell 
once they are phosphorylated by Tk-1. Compounds radiolabeled with PET isotopes can 
be used to identify Tk-1 activity with PET. In the GS reporter mouse, Tk-1 is under the 
control of the GS promoter and expressed in Wnt/ β-catenin signaling active cells, 
since GS is a target of β-catenin signaling (Loeppen et al. 2002). Thus, the growth of 
Ctnnb1 mutated tumors, characterized by excessive β-catenin signaling, can be 
reported with PET. In this doctoral thesis, the commonly known PET tracer 18F-FHBG 
(9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine) (Gambhir et al. 2000, Alauddin and 
Conti 1998) was used. It is likely that 18F-FHBG entered the cell via nucleotide 
transporters, as compounds with similar structures do (Mahony et al. 1988, Mahony et 
al. 1991, Green et al. 2004). Then, 18F-FHBG is trapped in Tk-1 reporter expressing cells 
once it is phosphorylated by Tk-1. 18F-FHBG is an acylguanosine and incorporates in the 
DNA (Alauddin et al. 2004, Green et al. 2004). Mammalian thymidine kinase, not from 
herpes simplex virus, will only lead to some minimal background phosphorylation 
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(Green et al. 2004). By applying simultaneous PET and MRI imaging, specificity and 
sensitivity for early tumor detection should be increased. Preliminary tests showed a 
rapid diffusion of the tracer 18F-FHBG in the mouse body after tail vein injection. A long 
lasting PET signal was observed in gut and kidney. This was due to the ways of 
excretion of the tracer 18F-FHBG. Yaghoubi et al. 2001 reported the primary clearance 
of 18F-FHBG through the renal and hepatobiliary way in humans. Although GS was 
expressed in the brain as seen with X-Gal staining, GS could not be detected in the 
brain with PET. The reasoning behind this is the inability of the tracer to cross the 
blood-brain barrier (Yaghoubi et al. 2001). In the liver, the PET signal was low. This 
offered a particularly good basis for detecting pathological changes accompanied by 
GS promoter activation during hepatocarcinogenesis. 
The last part of this work was to life image the development of liver tumors with non-
invasive technologies. Thus GS reporter mice were first initiated with DEN and 
promoted with PB for 25 weeks to generate liver tumors. This treatment scheme 
(Moennikes et al. 2000) produces liver tumors with a prevalence of nearly 80 % 
mutated in Ctnnb1 (Aydinlik et al. 2001), while only few tumors are mutated in Ras or 
Raf. Ctnnb1 mutated tumors have enhanced GS expression and could therefore have a 
selection advantage due to the independence from external glutamine over GS 
negative tumors (Gebhardt et al. 1989). Contrary to the expectations, Ctnnb1 mutated 
liver tumors could these not be visualized with PET using the Tk-1 reporter system. 
Tk-1 is under the control of the GS promoter and expressed in Ctnnb1 mutated cells. 
Therefore, Tk-1 was expected to be active in these tumors. Unfortunately, however, 
we were unable to obtain specific signals in the PET analysis of tumor-bearing mice, 
even though the tumors stained post-mortem were positive for GS as demonstrated by 
immunohistochemistry and LacZ staining and the presence of tumors in the GS 
reporter mice could be demonstrated by MRI. In the post-mortem analysis, some GS 
positive liver tumors showed less intensive LacZ staining than others, although all of 
the examined liver tumors were mutated in the Ctnnb1 gene. The phenotype of the 
Ctnnb1 mutated was like the one known from previous studies in our laboratory 
(Loeppen et al. 2005): the tumors were GS positive and showed the expected 
expression of Cyp1a2 and Cyp2c. We have no explanation why PET failed to detect the 
Ctnnb1 mutated, GS positive liver tumors in this experiment. A tissue dependent 
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detection limit of PET with 18F-FHBG was reported in literature with a magnitude from 
106 malignant glioma cells (Su et al. 2004) to 104 cells in a prostate tumor (Johnson et 
al. 2009). Ctnnb1 mutated liver tumors with a diameter of 1 mm in size contain less 
than 106 cells, as for solid tumors presumed (Pachmann 2012), since PB promotion 
leads hepatocellular hypertrophie as reported by Holsapple et al. 2006 and Elcombe et 
al. 2014 and to loosening-up of the cellular architecture. Thus, fewer cells per tumor 
are the result. Maybe Ctnnb1 mutated liver tumors contain too low numbers of cells to 
be detected with PET at week 25 of PB treatement, the latest time point of analysis in 
this study. Since one voxel in PET has a size of 0.8 mm3 (Schmid et al. 2012), it is 
potentially difficult to detect bulked and small liver tumors. Maybe, tumors will 
become detectable a few weeks later once they are larger in size. Another problem 
might be the tracer injection into the anesthetized animal, since inadequate tracer 
distribution might result. In general, acylguanosines, to which 18F-FHBG belongs, have 
two disadvantages compared to pyrimidin nucleosides, the other group of Tk-1 
substrates. First, acylguanosines are much less sensitive (Alauddin et al. 2004). Second, 
they are cleared via the hepatobiliary way, resulting in high amounts of radioactivity in 
the gallbladder and the intestine, as observed in this thesis and by Gambhir et al. 1998. 
The absence of a specific PET signal in our study was not due to a lack of tumor 
response in the treated animals. Tumor manifestation was clearly visualized by MRI in 
our study. It can not be discriminated by this technology, however, between Ctnnb1, 
Ha-ras and B-raf mutated liver tumors. All liver tumors appeared in the MRI image as 
bright areas with a sharp border. However, there are limitations of this in vivo imaging 
technique as the detection limit of mouse liver tumors in MRI is ~1 mm (Schmid et al. 
2012). Further experiments to generate larger Ctnnb1 mutated liver tumors are 
planned and will show if monitoring of these tumors with PET is possible. If PET 
detection of liver tumors should then work, we would have a tool to categorize the 
phenotype of liver tumors non-invasively. Furthermore, the reporter mouse model 
could be used to monitor the therapeutical outcome of tumor treatment regimens. 
Thus, new types of anti-cancer treatments could be tested non-invasively. 
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6. Summary (english) 
Carcinogenesis is a progressive multistep progress comprising various genetic alterations such 
as mutations in tumor suppressor genes and oncogenes. Non-genotoxic carcinogens (NGC) 
induce tumor formation by mechanisms other than changes in the underlying DNA sequence. 
Phenobarbital (PB) is a classic non-genotoxic carcinogen leading to perturbations in gene 
expression and DNA methylation. In mice, PB selects for Ctnnb1 (encoding β-catenin) mutated 
liver tumors. Recently, non-coding RNAs from the Dlk1-Dio3 cluster were identified as 
potential biomarkers for mouse liver tumor promotion caused by PB. One gene within this 
imprinted region is named Gtl2/ Meg3. 
We could show that Gtl2 expression was elevated in mice treated with substances of the PB 
type like PCB 153 and conazole funizides. But the transferability of the biomarker potential of 
Gtl2 to rats was limited. Using a switchable Gtl2 expressing hepatoma cell line, we found out 
that the expression of several microRNAs, immune system genes and olfactory receptors were 
altered with enforced Gtl2 expression. A supposable mechanism to regulate olfactory receptor 
and immune system gene expression could be via the polycomb repressive complex 2. Due to 
the lack of an appropriate Gtl2 knockout mouse model, Gtl2 was constitutively overexpressed 
in murine liver by the use of adenoviral Gtl2. There, Gtl2 was found to regulate cell cycle 
genes. No final decision could be made whether Gtl2 serves as a tumor suppressor as 
proposed in literature or as a tumor promoter suggested by members of the MARCAR 
consortium. There were supports for both characteristics. An initiation promotion study in a 
mouse constitutively overexpressing Gtl2 would help to answer this question. 
The second part of this work was to generate a glutamine synthetase (GS) gene expression 
“atlas” in a GS reporter mouse, which indirectly predicts in which organs/ cells Wnt signaling is 
active. Most GS promoter activity was found in brain, liver, kidney, testis and heart. In 
addition, the growth of GS positive liver tumors was pursued non-invasively in the GS reporter 
mouse by MRI, whereas PET failed to visualize small GS positive liver tumors. 
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7. Zusammenfassung (deutsch) 
Karzinogenese ist einen fortschreitender, mehrstufiger Prozess, der verschiedene genetische 
Veränderungen wie Mutationen in Tumorsuppressorgenen und Onkogenen umfasst. Nicht-
genotoxische Karzinogene (NGC) induzieren die Tumorbildung durch Mechanismen ohne die 
zugrundeliegende DNA Sequenz zu verändern. Phenobarbital (PB) ist ein klassischer Vertreter 
der nicht-genotoxischen Karzinogene, das zu Veränderungen in der Genexpression und DNA 
Methylierung führt. In Mäusen selektiert PB für Ctnnb1 (codiert für β-Catenin) mutierte 
Lebertumore. Kürzlich wurden nicht-kodierende RNAs aus dem Dlk1-Dio3 Cluster als 
potentielle Biomarker für Lebertumore der Maus identifiziert, die durch PB verursacht wurden. 
Ein Gen innerhalb dieser imprinteten Region ist Gtl2/ Meg3. 
Wir konnten zeigen, dass die Gtl2 Expression in Mäusen erhöht war, die mit Substanzen des PB 
Typs wie PCB 153 und Conazol Fungiziden behandelt wurden. Jedoch war die Übertragbarkeit 
des Biomarkerpotentials von Gtl2 auf Ratten begrenzt. Durch Verwendung einer schaltbaren, 
Gtl2 exprimierenden Leberkrebs-Zelllinie fanden wir heraus, dass die Expression von mehreren 
microRNAs, von Genen des Immunsystems und olfaktorischen Rezeptoren durch verstärkte 
Gtl2 Expression verändert war. Ein denkbarer Mechanismus für die Regulation der Expression 
von olfaktorischen Rezeptoren und Genen des Immunsystems könnte über den polycomb 
repressive complex 2 ablaufen. Aufgrund des Mangels an einem geeigneten Gtl2 knockout 
Mausmodell wurde Gtl2 durch adenovirales Gtl2 in der Mausleber konstitutiv überexprimiert. 
Dabei wurde Gtl2 als Regulator der Gene des Zellzyklus identifiziert. Es konnte aber keine 
abschließende Entscheidung getroffen werden, ob Gtl2 als Tumorsuppressor fungiert, wie in 
der Literatur vorgeschlagen, oder aber als Tumorpromoter, wie Mitglieder des MARCAR 
Konsortiums annehmen. Es gab Hinweise für beide Möglichkeiten. Ein Initiations-Promotions-
Experiment in Mäusen, die Gtl2 konstitutiv überexprimieren, würde helfen, diese Frage zu 
beantworten. 
Der zweite Teil dieser Arbeit befasste sich mit dem Anlegen eines Glutaminsythetase (GS) 
Expressions-Atlases in einer GS Reportermaus, wodurch indirekt vorausgesagt werden kann, in 
welchen Organen/ Zellen der Wnt Signalweg aktiv ist. Am meisten GS Promoteraktivität wurde 
in Gehirn, Leber, Niere, Hoden und Herz gefunden. Zusätzlich wurde das Wachstum GS 
positiver Lebertumore in der GS Reportermaus durch MRT nicht-invasiv verfolgt, wohingegen 
es misslang, kleine GS positive Lebertumore mit PET sichtbar zu machen. 
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Figure 46: Organ slices of male (left) and 
promoter activity. (1) cerebellum, (2) hippocampus, (3) caudate/ putamen, (4) salivary gland, (5) thyroid gland, (6) 
esophagus & trachea, (7) stomach, (8) duodenum, (9) jejunum, (10) Ileum, (11) coecum, (12) colon proximal, (13) 
colon medial, (14) colon distal, (15) pancreas, 
gland, (21) urinary bladder, (22) ovary, (
muscle, (30) sternum. For localization of β
# Male GS mouse 
1 
2 
3 
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female (right) GS mice stained with β-galactosidase, reflecting GS 
(16) liver, (17) gall bladder, (18) spleen, (19) kidney, (20) adrenal 
23) uterus, (24) cervix, (25) testis, (26) heart, (27) thymus, (28) lung, (29) 
-galactosidase positive cells, please see table 21. 
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